{
  "id": "benign-prostatic-hyperplasia",
  "title": "Benign prostatic hyperplasia",
  "lang": "en",
  "source_lang": "en",
  "summary": "Benign prostatic hyperplasia is a non-malignant enlargement of the prostate, common in older men, that becomes clinically important when it narrows the urethra or affects bladder function.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "benign prostatic hypertrophy",
    "BPH",
    "prostate enlargement",
    "良性前列腺增生症",
    "前列腺增生"
  ],
  "generated_at": "2026-10-09",
  "model": "pro/claude-haiku-5-5",
  "url": "https://aiwiki.page/en/benign-prostatic-hyperplasia/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/benign-prostatic-hyperplasia/",
      "json": "https://aiwiki.page/zh/benign-prostatic-hyperplasia.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate gland caused by the proliferation of its cellular elements. It is a histological diagnosis: the growth is most often concentrated in the transition zone around the urethra, and it becomes clinically important when the enlarged tissue narrows the urethra or changes bladder function. It is closely tied to ageing and to male hormone physiology, and it is one of the most common chronic conditions in older men, so its management touches epidemiology, clinical medicine and public health alike. The condition is distinct from prostate cancer, although the two can coexist and share a diagnostic test, prostate-specific antigen.\n\nThe entry explains how BPH develops and why it produces symptoms. It covers the androgen pathway in which testosterone is converted by 5α-reductase into dihydrotestosterone, the stromal and epithelial growth processes, and the smooth-muscle tone of the prostate and bladder neck that determines how much obstruction a given gland causes. It then describes the bladder changes that follow chronic outflow resistance, the symptoms and complications seen in practice, and the steps of diagnosis that separate BPH from cancer and other causes of urinary symptoms.\n\nThe second half of the entry addresses treatment. It compares watchful waiting and conservative measures with drug classes such as α-blockers, 5-α-reductase inhibitors, combination therapy and phosphodiesterase-5 inhibitors, and with surgical and minimally invasive procedures chosen largely by prostate size. It also traces how guideline recommendations have changed, what the open questions are about causes and progression, and how the field's understanding has developed from early open surgery to current endoscopic and office-based options."
    },
    {
      "heading": "Definition and pathological nature",
      "text": "Benign prostatic hyperplasia (BPH) is a histological diagnosis. It describes the proliferation of both stromal and epithelial elements in the prostate, which produces nodular enlargement of the gland. Because the diagnosis rests on tissue, it is not the same thing as the clinical syndrome of lower urinary tract symptoms (LUTS), even though the two often occur together.\n\nHistological features\n\nUnder the microscope, BPH nodules contain glandular and stromal components in varying proportions. Some nodules are dominated by stroma, which includes smooth muscle and fibroblasts, while others are predominantly glandular. The tissue is non-malignant. Its cells show no significant nuclear atypia, the basal cell layer is preserved, and the lesion does not invade surrounding tissue. Adenocarcinoma, by contrast, typically lacks a basal cell layer, and this difference is one of the features pathologists use to tell the two apart. Benign and malignant change can coexist in the same gland, which is why pathological assessment matters even when the nodules look like BPH.\n\nHistological BPH is strongly age-related. Autopsy series from the 1970s and 1980s, including work by Berry and colleagues, found the lesion in a minority of men in their thirties and forties and in a large majority of men in their eighties. Clinical findings broadly agree with this pattern, although the age at which men become symptomatic varies widely.\n\nTerminology: hyperplasia and hypertrophy\n\n\"Hyperplasia\" refers to an increase in the number of cells, whereas \"hypertrophy\" refers to an increase in the size of individual cells. The condition is predominantly hyperplastic, since the nodules result from cell proliferation, although some stromal smooth-muscle cells also enlarge. The older name \"benign prostatic hypertrophy\" was used widely in twentieth-century clinical practice and remains common in lay usage. The term \"hyperplasia\" was adopted to describe the underlying process more accurately, and the abbreviation BPH was kept. Earlier surgical literature also used \"prostatic adenoma\", a misleading label, since the lesion is not a true neoplasm.\n\nAnatomical, symptomatic and functional distinctions\n\nThree levels of the condition should be kept separate. The first is anatomical BPH, meaning the enlarged gland with its histological nodules. The second is LUTS, the symptoms a man experiences, such as a weak stream or frequent urination. The third is bladder outlet obstruction (BOO), a functional consequence in which the enlarged gland and its dynamic tone impede urine flow. These levels correlate only loosely. Some men with substantial histological BPH have few symptoms, some men with small glands have marked obstruction, and LUTS can arise from causes other than BPH, such as overactive bladder. Clinical assessment therefore treats gland size, symptom burden and objective obstruction as separate variables. The mechanisms of enlargement and obstruction are discussed in later sections."
    },
    {
      "heading": "Prostate anatomy and zonal origin",
      "text": "The prostate is conventionally divided into four zones: the peripheral zone, the transition zone, the central zone and the anterior fibromuscular stroma. The peripheral zone forms the postero-inferior part of the gland and accounts for roughly 70% of the glandular volume in a young man. Most prostate cancers arise there, which is one reason the zonal layout matters clinically. The central zone encircles the ejaculatory ducts and contains about 20–25% of the volume; it is a frequent site of inflammatory change. The anterior fibromuscular stroma is a band of predominantly fibromuscular tissue lying in front of the other zones, separating the urethra and glandular tissue from adjacent structures.\n\nThe transition zone is the site where BPH develops. In a normal gland it contains only about 5% to 10% of the glandular volume, depending on the source, but in BPH it can account for up to 80% of that volume. It consists of two lateral lobes and a periurethral gland region that surrounds the proximal urethra between the bladder base and the verumontanum. The proliferating stromal and epithelial cells form discrete nodules in this periurethral tissue. As the nodules enlarge, they compress the urethra, can extend the transition zone below the verumontanum, and may push the peripheral zone flat against the gland's outer boundary. In large glands, a median lobe can also project into the bladder, an arrangement that changes both symptoms and treatment choice.\n\nPeriurethral growth and the surrounding capsule\n\nBecause the transition zone is wrapped around the urethra at the bladder outlet, its expansion narrows the lumen directly rather than displacing the gland outward. The anterior fibromuscular stroma resists growth in front, so enlargement tends to proceed laterally, posteriorly and toward the bladder neck. A fibrous plane separates the transition zone from the peripheral zone, and this plane is often described as a pseudocapsule: a compressed layer of peripheral-zone tissue that forms the boundary used during enucleation. The true prostatic capsule encloses the whole gland.\n\nThe traditional mechanical account holds that the fibrous capsule limits radial expansion of the enlarging gland, so that growth compresses the urethra inward. This model explains the static, obstructive component of the disease, but it is incomplete, since bladder dysfunction and smooth-muscle tone also contribute substantially to symptoms. The mechanism of obstruction is therefore discussed further in the sections on dynamic obstruction and bladder consequences.\n\nRelevance to imaging, biopsy and surgery\n\nOn magnetic resonance imaging, the enlarged transition zone typically appears heterogeneous on T2-weighted sequences, because hypointense stromal tissue is interspersed with hyperintense cystic and glandular elements. Recognising the zonal boundaries is essential to separate benign nodules from a lesion in the peripheral zone. The same is true of transrectal ultrasound, which is used to estimate volume and to guide the planning of biopsy sampling. Because the transition zone is distorted in BPH, sampling strategy must account for the displaced peripheral zone, which can be thinned and difficult to reach.\n\nZonal anatomy also governs surgical technique. Transurethral resection removes transition-zone tissue from the inside outward, whereas enucleation techniques use the surgical capsule as a dissection plane to separate the adenoma from the peripheral zone. Preservation of the anterior fibromuscular stroma and the management of a median lobe influence the choice between these approaches. Earlier interventions can also alter the imaging picture: ablation creates areas of necrosis that distort the boundary between the transition and peripheral zones, prostate artery embolisation produces infarcts within the transition zone, and some implanted devices create susceptibility artefacts that may obscure a transition-zone lesion on MRI. Follow-up imaging after treatment therefore needs to be interpreted with knowledge of these changes."
    },
    {
      "heading": "Epidemiology and risk factors",
      "text": "Histological prevalence and age\n\nHistological BPH becomes more common with each decade of life. Autopsy series, which detect the lesion in tissue regardless of symptoms, remain the main reference point. A widely cited summary of these studies gives a histological prevalence of about 8% in the fourth decade, 50% in the sixth and 80% in the ninth. Later reviews report similar figures, with roughly 50–60% of men in their sixties and 80–90% of men over seventy showing the lesion. One older autopsy series found histological BPH in 88% of men over eighty.\n\nThe steepness of this curve reflects a process that compounds over time. Longitudinal estimates suggest that prostate volume increases by about 2–2.5% per year, so small annual gains accumulate into large enlargement across decades. Because histology is the most direct measure, these autopsy figures are often treated as a baseline against which symptom-based and imaging-based estimates are compared.\n\nPopulation burden and lower urinary tract symptoms\n\nSymptom prevalence follows the same upward trend but runs at a lower level than histology, because most men with histological change do not have bothersome symptoms. In a Boston-area community survey, the prevalence of male lower urinary tract symptoms rose from 8% among men aged 30–39 to 35% among men aged 60–69. In the Olmsted County study, the prevalence of moderate-to-severe symptoms climbed to nearly half of men by their eighties. The Multinational Survey of the Aging Male reported moderate-to-severe symptoms in 31% of men aged 50–80 in Europe and the United States, while a UK community sample recorded 41%. In a Swedish population cohort of men aged 50–69, only about 25% reported moderate or severe symptoms.\n\nThe Global Burden of Disease 2019 analysis estimated an age-standardised BPH prevalence of 2,480 per 100,000 people, with regional values ranging from 987 per 100,000 to 6,480 per 100,000 in eastern Europe. These modelled estimates were produced without a preceding systematic review, which the authors acknowledged, so the regional differences should be read with caution.\n\nRisk factors and strength of evidence\n\nAge is the strongest and most consistent risk factor. Family history is also frequently mentioned, and one review notes that the available data suggest an autosomal dominant pattern, although the genetic evidence is limited and no specific gene has been firmly established.\n\nObesity has the most extensive observational support among modifiable factors. In the Health Professionals Follow-up Study, men with a waist circumference above 109 cm had a 2.4-fold higher risk of surgical treatment for BPH. A 2009 review found strong positive associations across body mass index, waist circumference and waist-to-hip ratio, and consistent links between adiposity and radiographically measured prostate volume. Proposed mechanisms include hyperinsulinaemia, and the conversion of testosterone to oestrogen in adipose tissue.\n\nMetabolic syndrome has been studied less consistently. In a prospective cohort of Han Chinese men, central obesity and low high-density lipoprotein cholesterol were independently associated with clinical BPH after mutual adjustment, with hazard ratios of 1.93 and 1.56 respectively. Proposed pathways include insulin resistance, increased autonomic activity, Rho kinase activity, low-grade inflammation and altered sex hormone levels. Whether the syndrome as a whole, or individual components, drives the association remains unresolved, and some studies have grouped participants in ways that prevent separating these effects.\n\nPhysical inactivity is associated with higher BPH risk in cohort data from the Health Professionals Follow-up Study and the Massachusetts Male Aging Study, and most published studies report that greater activity lowers risk. Dietary associations are weaker: red meat and high fat intake have been linked to increased risk, and higher vegetable intake to decreased risk, but these findings come mainly from observational research. Caffeine intake has been associated with BPH progression rather than clearly with onset. Smoking, alcohol and short sleep duration are discussed as possible contributors, but direct evidence for them is more limited.\n\nPopulation differences and limits of the data\n\nEstimates depend heavily on how BPH is defined. Investigators have used histological analysis, imaging-detected enlargement, reduced urinary flow rate, urodynamic obstruction, surgery, acute urinary retention, physician diagnosis and questionnaire-based symptom scores. Each captures a different part of the disease, and this diversity makes it difficult to compare risk factors across studies. One review noted that cumulative prostatism matched autopsy prevalence in one analysis, yet most cohorts rely on broader or narrower definitions.\n\nPopulation-level comparisons are also affected by measurement and access. In a Ghanaian study, 40% of men had an enlarged prostate on ultrasound, a figure that depends on imaging thresholds rather than histology. In the BACH survey, the five-year incidence of moderate-to-severe symptoms was 7% among White men and 13% among men from other racial groups. Surgery-based definitions further depend on health-system access and clinical practice, so they can understate the true burden in populations with limited care. Taken together, the available data show a clear age gradient and a plausible role for metabolic and lifestyle factors, but they provide weaker evidence on how these factors interact with genetics and with each other."
    },
    {
      "heading": "Androgen and hormonal mechanisms",
      "text": "Local conversion of testosterone to DHT\n\nMost circulating testosterone is made in the testes, but within the prostate it is converted by 5α-reductase into dihydrotestosterone (DHT). About 90% of testosterone in the prostate is converted to dihydrotestosterone, and the reaction is effectively one-way. DHT is therefore a tissue-level androgen: its effects depend on what the prostate itself produces rather than on serum concentrations alone. Two isoenzymes perform this step. Type 1 5-alpha reductase is expressed mainly in epithelial cells, while type 2 5-alpha reductase is expressed mainly in stromal cells. Type 2 5-alpha reductase is expressed in some basal epithelial cells, which gives the type 2 enzyme a central role in the stromal compartment where most BPH growth is thought to originate. Its activity is also linked to tissue levels: elevated SRD5A2 activity has been associated with increased intraprostatic DHT levels and larger prostate volumes. DHT is the more potent ligand as well, with a longer half-life and a higher affinity for the androgen receptor than testosterone.\n\nAndrogen receptor signalling\n\nDHT exerts its effects through the androgen receptor (AR), a nuclear transcription factor. Once the hormone binds, the receptor-ligand complex regulates the expression of target genes. These downstream transcriptional programs promote cellular proliferation and differentiation. In the prostate, this signalling is thought to shift the balance toward growth: one review states that androgenic hormones, particularly DHT, drive prostate growth by activating signaling pathways that enhance cell proliferation and inhibit apoptosis, linking the hormonal stimulus to the cell death component discussed elsewhere. Because DHT stimulates both epithelial and stromal proliferation, the receptor pathway is relevant to both compartments.\n\nAge-related hormonal change and the estrogen hypothesis\n\nThe estrogen hypothesis rests on the observation that the hormonal ratio changes with age. In men, serum androgen levels decrease during aging while the levels of 17β-estradiol remain constant, increasing the ratio E2/T. Adiposity is a proposed driver of this shift, since adipose tissues express the aromatase enzyme, which converts testosterone to estrogen, and adiposity tends to increase with aging, while testosterone production by the testes tends to decrease. Local production is also proposed: estrogen is produced locally within the prostate via conversion of testosterone to 17β-estradiol by the aromatase enzyme expressed within the prostate stroma.\n\nSupporting evidence includes animal work. Treatment of dogs with estrogen, in addition to androgens, leads to the development of BPH and LUTS, and preclinical models of LUTS/BPH have shown that ERα activation contributes to disease initiation and progression. Human associations are less consistent. Some reviews argue that not only low testosterone but also high estradiol can favor BPH/LUTS progression, yet other analyses note that a clear dose-response relationship between circulating androgen levels and BPH has never been demonstrated, and one review concluded that no evidence for the role of testosterone (T) or dihydrotestosterone (DHT) is found in BPH initiation. Within the androgen model itself, the apparent paradox is that during male senescence, androgens tend to decrease and not to increase, and in hypogonadal men LUTS can even be lessened by androgen supplementation. Experimental data also show that in healthy men, medical castration using a long-acting GnRH antagonist reduces intraprostatic T and DHT substantially without changing prostate cell proliferation, apoptosis or androgen-regulated protein expression, which suggests that the relationship between intraprostatic androgen and growth is not simple.\n\nCastration and early androgen deficiency\n\nThe strongest clinical support for androgen dependence comes from the effects of castration and of developmental androgen deficiency. Observations date to the eighteenth century: in 1786, John Hunter observed that castrated bulls had small prostates. In 1895, White presented a series of 111 cases demonstrating that bilateral castration led to decreased prostate size and improvement in urinary function in some patients, although this series did not distinguish among patients with BPH and advanced prostate cancer. Modern imaging has confirmed the volume effect; MRI and ultrasound have demonstrated that androgen withdrawal does significantly decrease prostate size. Developmental timing matters. Men castrated before puberty do not develop nodular hyperplasia, and men with hypopituitarism leading to low serum androgens do not develop BPH. Similarly, 5α-reductase deficiency in humans is an uncommon genetically transmitted disorder in which prostate size remains very small throughout adult life.\n\nThese findings establish androgens as a permissive requirement rather than a sufficient cause. Many lines of evidence support that androgens are permissive but insufficient for the induction and maintenance of BPH. The volume reduction produced by androgen deprivation also does not map neatly onto symptom relief, as increased prostate volume does not always correlate with the clinical syndromes of LUTS, a point that bears on the separation between gland size and symptoms."
    },
    {
      "heading": "Cellular growth, stromal–epithelial interactions and cell death",
      "text": "Imbalance between proliferation and apoptosis\n\nGrowth in the ageing prostate reflects a shift in the balance between cell proliferation and apoptosis. Within hyperplastic nodules, the equilibrium between stromal growth and stromal death is disturbed, and the net result is an accumulation of stromal volume. Compared with normal prostatic tissue, the balance between growth and apoptosis of stromal cells in hyperplastic nodules is lost, finally leading to an increase in stromal volume. Quantitative comparisons put the difference in scale in perspective. In one review, proliferation indices are reported at roughly 9-fold higher for epithelium and 37-fold higher for stroma relative to normal prostate tissue, which is the basis for describing BPH as stromal-dominant.\n\nThis stromal predominance is not uniform across glands. Stromal hyperplasia predominates in large prostates, whereas epithelial hyperplasia is more common in small prostates. The mechanism behind stromal expansion in large glands is less clear, because some studies found that stromal proliferative activity in large prostates was comparable with that in small prostates, which suggests that the source of the hyperplastic stromal cells remains open. An epithelial-mesenchymal transition has been proposed as one source, but this idea remains controversial because many nodules consist mainly of stroma with little epithelial involvement.\n\nParacrine signalling between stroma and epithelium\n\nProstatic development and adult tissue maintenance depend on androgen-dependent reciprocal paracrine interactions between stromal and epithelial components. In BPH, this signalling appears to be disturbed in a way that partly bypasses androgen control. Stromal cells can use growth factor pathways, including epidermal growth factor, basic fibroblast growth factor, insulin-like growth factor and transforming growth factor β1 (TGF-β1), to switch on androgen-sensitive genes in an androgen-independent way.\n\nThe fibroblast growth factor family is particularly well studied in this setting. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. Interleukin-1α acts as a paracrine inducer of FGF7, a key epithelial growth factor, and interleukin-8 induces FGF2, which acts on both stromal and epithelial cells. Taken together, the overexpressed growth factors and interleukins are thought to create an environment that favours stromal and epithelial growth and mesenchymal transdifferentiation.\n\nChronic inflammation, immune infiltrates and cytokines\n\nInflammatory infiltrates are present in nearly all histological specimens, although a consistent link to bacteria or other foreign antigens has not been established. The infiltrate is dominated by chronically activated CD4+ T lymphocytes, which are permanently recruited to prostate tissue via elevated expression of interleukin 15 (IL-15) and interferon γ (IFN-γ). By composition, the infiltrate is roughly 70% chronically activated T cells, 15% B lymphocytes and 15% macrophages. As tissue matures, cytokine profiles change: IFN-gamma and IL-2 reach about 10-fold higher levels in fully developed BPH than in normal prostates, while TGF-β is about 2-fold higher. In mature nodules, IL-4 and IL-13 also rise, pointing to a shift toward a Th2-type pattern.\n\nCytokines link inflammation to proliferation. IL-8 has been proposed as a direct bridge between chronic inflammation and autocrine and paracrine stromal growth, and it mediates epithelial and stromal cell proliferation. The prostatic cells themselves are also sources of these signals: TLR activation in BPH cells leads to the production of proinflammatory cytokines (IL-6) and of chemokines (IL-8 and CXCL10) able to recruit infiltrating cells. In cell-line experiments, the proinflammatory cytokine macrophage migration inhibitory factor promoted proliferation and suppressed apoptosis in BPH epithelial cells, and these effects were partly reversed by pharmacological inhibition. Inflammation is commonly framed as a wound-healing response in which inflammation-induced damage of the prostatic tissue represents a chronic process of wound healing which activates hyperproliferative programmes resulting in BPH nodules. Proposed initiators include bacterial infiltration, autoimmune-like responses and repeated mechanical microtrauma, but these remain hypotheses.\n\nLimits of current understanding\n\nThe cellular mechanisms driving this growth remain incompletely defined. The exact molecular mechanisms remain incompletely elucidated. Researchers do not yet know the point at which chronic immune inflammation begins in BPH, nor its primary initiators. The processes also differ in an important way from neoplastic growth. BPH nodules arise mainly in the transition zone of the prostate, whereas prostatic intraepithelial neoplasia and prostate cancer mainly arise in the prostate gland from epithelial cells, localized in the peripheral zone. Chronic inflammation has been associated with both conditions, so inflammatory markers alone do not separate hyperplasia from malignancy."
    },
    {
      "heading": "Dynamic obstruction and smooth-muscle tone",
      "text": "Static and dynamic components\n\nBladder outlet obstruction in BPH is usually described as having two components. A 1975 study by Caine and colleagues found large numbers of alpha-adrenergic receptors in the smooth muscle of the prostatic capsule and bladder neck, which supported the view that the obstruction has both a static and a dynamic part. The static component is the mechanical one: progressive hyperplasia of the prostate with aging leads to urethral narrowing. The dynamic component is the variable contraction of smooth muscle, which is controlled by the sympathetic nervous system and changes with stress, cold and sympathomimetic drugs. Because this tone can shift quickly, it explains the often rapid fluctuations in symptoms that patients report.\n\nLater estimates suggest the balance between the two components varies between men. One review states that the resulting tone is believed to contribute substantially to the total urinary outflow obstruction observed in patients with BPH, with the remaining being attributable to increased prostate mass.\n\nAlpha-1 receptors in the stroma, capsule and bladder neck\n\nAlpha-1 adrenoceptors belong to the G protein coupled receptor family. Molecular cloning identified three subtypes, but the link between any individual subtype and its functional role in the body has remained elusive. In human prostate tissue, the subtype question was addressed mainly by radioligand binding and in vitro contraction studies. Binding work in the early 1990s concluded that the dominant alpha 1 subtype in the human prostate is the alpha 1A. A later review placed the receptors mainly in stromal cells, reporting that the alpha-1A subtype accounts for 70%-100% of adrenoceptors in prostatic stroma, and that in situ hybridization has confirmed that stromal cells are the predominant location of these receptors.\n\nNot all groups agreed on the subtype. A 1994 study of prostatic tissue from patients undergoing open prostatectomy concluded that the receptor is best represented as the alpha-1C subtype, and the nomenclature has remained confusing since then. Regardless of subtype, the receptors act on the outflow tract. Stimulation of alpha-1 receptors produces contraction of urethral and bladder neck smooth muscle, leading to increased resistance in urinary outflow.\n\nSympathetic innervation and early binding studies\n\nEnlarged glands are thought to have a higher level of sympathetic input. One patent background describes increased noradrenergic innervation of the enlarged prostate leads to an increased adrenergic tone of the bladder neck and urethra. Pharmacological data point in the same direction: because baseline tone is present in prostate smooth muscle as a result of rich sympathetic innervation, blocking the receptors relaxes the tissue.\n\nThe first radioligand binding study of prostatic alpha-1 receptors used adenoma tissue, and it found that the receptor binding of [3H] prazosin in homogenates obtained from human prostatic adenomas was saturable and a single high affinity prazosin binding site was identified. The same study noted that the receptor density was not directly proportional to the weight of the surgically removed adenoma. This finding, which indicates that receptor number and gland mass are separate variables, is central to the dynamic model.\n\nPharmacological blockade and symptom relief\n\nAlpha-1 antagonists give clinical evidence for the dynamic component. Because alpha_1-adrenoceptors are sparse in the bladder, medical therapy aimed at blocking the alpha receptor will relieve bladder outlet obstruction without inhibiting bladder function. The mechanism is described as one in which alpha_1-antagonists (blockers) relax prostate smooth muscle and decrease urethral resistance, ultimately leading to relief of LUTS.\n\nThe clearest argument that this effect is separate from volume reduction is that pharmacologic antagonists of these receptors can notably improve symptoms, even in patients who have undergone prostatectomy. Most clinically used alpha blockers do not discriminate strongly between subtypes: in one comparison, prazosin, terazosin, doxazosin, alfuzosin, and abanoquil showed no selectivity for the human alpha 1 subtypes.\n\nThe relationship is not fully settled. In vitro work has shown that doxazosin can induce apoptosis in prostatic stroma, and one proposal holds that apoptosis-mediated prostate stromal regression appears as a molecular mechanism underlying the therapeutic response to alpha_1 blockade in the treatment of BPH. Thus the acute relaxation and any longer-term tissue effects may both contribute to symptom change, and the distinction between them is still under study."
    },
    {
      "heading": "Bladder dysfunction and the consequences of outflow obstruction",
      "text": "When the prostatic urethra narrows, the detrusor muscle of the bladder must generate higher pressure to empty. Its response is largely adaptive. Histological studies of obstructed human bladders report that detrusor smooth-muscle cells have a larger diameter than those of controls, and that the extracellular matrix gains increased accumulation of collagen and elastic fibers. Over time, this combination makes the wall thicker and stiffer. On cystoscopy, the wall may show ridges between muscle bundles, and where the mucosa herniates through these gaps, small pouches called cellules or diverticula can form. Increased pressure associated with micturition and bladder distention can progress to hypertrophy of the bladder detrusor, trabeculation, cellule formation, and diverticula.\n\nStructural remodelling changes how the bladder stores urine as well as how it empties. Higher intravesical pressure makes the bladder wall more sensitive, so that it contracts involuntarily during filling. The clinical result is the overactive pattern of frequency, urgency and nocturia. This increased sensitivity (detrusor overactivity), even with small volumes of urine in the bladder, is believed to contribute to urinary frequency and LUTS. Remodelling also reduces detrusor compliance, meaning the bladder can hold less urine at a safe pressure. Storage symptoms in BPH therefore do not always reflect irritation from the prostate itself.\n\nA widely used conceptual model describes the bladder's course in three phases. A three-stages model of bladder wall remodeling can be hypothesized involving an initial hypertrophy phase, a subsequent compensation phase and a later decompensation. In the compensated phase, the muscle still expels urine effectively, although it works harder. In the decompensated phase, the contractile apparatus of the detrusor weakens. Experimental and clinical data suggest that the transition from early compensated to the later decompensated detrusor function being central to disease progression. Chronic obstruction can therefore lead to detrusor underactivity, in which the bladder contracts poorly and leaves more urine behind. This produces emptying symptoms: low urinary stream, hesitancy, intermittency, and increased residual urine. Because the same symptoms can arise from a weak bladder or from an obstructed outlet, urodynamic testing is used to separate the two. Urodynamic studies - To help distinguish poor bladder contraction ability (detrusor underactivity) from BOO. Some men show overactivity and underactivity at different times, so the bladder's state can change over the course of the disease.\n\nPressure generated in the bladder can also travel upward. In severe bladder-outlet obstruction, pressure can build in the bladder and transmit backward through one or both ureters. Remodelling at the junction between the ureter and the bladder can add a mechanical obstruction, and hydronephrosis is the typical result. In one older review, in men with BPH and increased serum creatinine, hydronephrosis is common (one-third). Renal failure in these patients is linked to bladder compliance: in one historical series of men with symptomatic BPH, a large share of those with low bladder compliance had renal failure. Hydronephrosis does not, however, invariably cause permanent injury. Its significance depends on how severe the dilation is, how long obstruction has been present, whether kidney function is impaired, whether infection is present, and whether the obstruction can be relieved promptly. For the broader kidney consequences, see chronic kidney disease and kidney.\n\nThese findings explain why bladder function often matters more than gland size in determining symptoms. Prostate volume correlates only loosely with symptom severity, because the pressure needed to void depends on how well the detrusor can compensate. A moderately enlarged gland can produce severe symptoms if the bladder has already decompensated, while a very large gland may cause few complaints in a well-compensated bladder. Once the bladder has remodelled, the high-pressure state can become self-sustaining: cellular and physiological changes in bladder muscle and collagen contribute to a high-pressure bladder that perpetuates itself with worsening ability to empty. This feedback helps explain why some men continue to have symptoms or renal problems after the obstruction is relieved."
    },
    {
      "heading": "Clinical presentation and symptom patterns",
      "text": "Men with an enlarged prostate usually come to attention because of a group of complaints that clinicians call lower urinary tract symptoms (LUTS). Gland size and the intensity of complaints are only loosely linked, and the same complaints can arise from other conditions, which is one reason the umbrella term is used (the clinical syndrome that often accompanies BPH has been described as lower urinary tract symptoms). Estimates vary by source: one review puts the share of men aged 50 to 65 with LUTS at up to 15% to 25%, and among men with histological BPH, approximately half report moderate-to-severe LUTS.\n\nVoiding and storage complaints\n\nComplaints about emptying the bladder, such as a delayed start, a weak or interrupted stream, straining, and the feeling that the bladder has not emptied, form the voiding group (voiding symptoms include weak or intermittent stream, straining, hesitancy, terminal or p). Storage complaints, including urgency, daytime frequency, nocturia and urge incontinence, are attributed to incomplete emptying, rapid refilling and changes in the bladder wall that prompt the bladder to contract at lower volumes (storage symptoms include nocturia, urgency, urinary frequency, and urinary incontinence. Storage symptoms arise from incomplete emptying and rapid refilling of the bladder and changes of the bladder wall). In mild disease, men most often report waking at night to urinate together with a weakened flow (the symptoms seen in early BPH are nocturia and slower urinary stream with sensation of incomplete voiding). Urgency paired with urge incontinence leads clinicians to suspect a later stage, in which the bladder itself has become affected (urinary urgency and urge incontinence). A minority of men also present with blood in the urine (some patients with BPH present with hematuria).\n\nStandardised scoring instruments\n\nThe most widely used tool is the International Prostate Symptom Score (IPSS). It was created in 1992 by the American Urological Association, and the WHO-sponsored consultation later adopted the \"eight question\" index and labeled it the IPSS. Seven items cover urinary symptoms, each scored from 0 to 5, giving a total of 0 to 35 (asymptomatic to very symptomatic), and the bands are mild (0 to 7), moderate (8 to 19), or severe (20 to 35). The eighth item addresses bother: it asks how the man would feel about living indefinitely with his current urinary condition, with answers ranging from \"delighted\" to \"terrible\" (0-6). The IPSS is a screening and monitoring instrument rather than a diagnostic test, since it cannot distinguish between benign prostatic obstruction (BPO), bladder dysfunction, infection, or pelvic floor hypertonicity.\n\nResearch studies add further outcome measures. One study of symptomatic men combined the IPSS with the IIEF-5 erectile function score, the Brief Sexual Function Inventory, urinary flow rate, prostate volume and serum testosterone (88 men with symptomatic BPH were investigated). The BPH Impact Index is used alongside the IPSS and covers physical discomfort, worry, how bothersome the symptoms are, and the level of interference with daily activities.\n\nAcute urinary retention\n\nAcute urinary retention (AUR) is the abrupt loss of the ability to void, and it is a medical emergency. It is one of the most significant complications to benign prostatic hyperplasia (BPH), and benign prostatic hyperplasia is the single most common cause in males. Triggers reported in the literature include prostate cancer, prostatitis, lower urinary tract infection (UTI), constipation, urethral stricture, genitourinary trauma, neurological injury or compromise, as well as drugs such as anticholinergics, centrally acting drugs, alpha agonists, alcohol and anaesthetics. Patient-facing sources also list over-the-counter cold and allergy medicines and prolonged immobility.\n\nRisk rises steeply with age. In the Olmsted County natural-history cohort, the risk of AUR was 1.6% at five years for men aged 40-49 years and 10% at 70-79 years. Population data show a more modest trend: a Danish cohort recorded an incidence that declined to 2.95 in 2017 after a transient rise. Prostate size and PSA are the main predictors. In one analysis, the incidence rate of AUR was significantly higher in patients with prostate volume ≥ 40 mL (4.2%) than patients with prostate volume < 40 mL (1.6%), and placebo-group risk increases dramatically with serum PSA levels above approximately 1.3 ng/mL. Recurrence is common: without alpha-blocker therapy, one review reports 76-83% recurrence in men with diagnosed BPH. Mortality is also substantial, as the Danish cohort found that mortality was 4–5 times higher after 3 months of AUR compared with the general population.\n\nSexual dysfunction and quality of life\n\nSexual complaints frequently accompany LUTS. A French study cited in one report placed the rate of erectile dysfunction in men with LUTS/BPH from 30% to 70%, and another analysis found that the degree of erectile dysfunction is correlated with symptoms of IPSS score. Ejaculatory function can also be affected, particularly by some drug treatments, a topic addressed in the pharmacological section. Symptom burden also reduces daily life, since bothersome urinary symptoms are usually associated with benign enlargement of the prostate gland that is of sufficient severity to interfere with a man's quality of life. Progression is variable: not all males suffering from BPH exhibit worsening or progression of symptoms, but in untreated men, peak urinary flow, voided volume, and symptoms may worsen over time."
    },
    {
      "heading": "Diagnostic evaluation",
      "text": "Diagnosis in routine practice rests mainly on clinical assessment. Tissue confirmation is rarely needed, because the treatment decision depends on how bothersome the symptoms are, whether other conditions explain them, and how much the enlarged gland contributes to obstruction.\n\nHistory, symptom scoring and examination\n\nFor men with bothersome lower urinary tract symptoms (LUTS) possibly caused by BPH, the current AUA guideline names four core steps: history, physical examination, the International Prostate Symptom Score (IPSS), and urinalysis. In the initial evaluation of patients presenting with bothersome LUTS possibly attributed to BPH, clinicians should obtain a medical history, conduct a physical examination, utilize the International Prostate Symptom Score (IPSS), and perform a urinalysis. The history is directed at urinary symptoms, earlier urological surgery and general health, including conditions that impair bladder function or increase urine production. It also records family history of prostate disease and fitness for possible surgery. Patient voiding diaries, where the frequency of micturition and urine volume is recorded, may be helpful in selected patients, especially in those with nocturia as the predominant symptom.\n\nThe IPSS and the AUA Symptom Index are near-equivalent self-completed questionnaires that grade severity across storage and voiding symptoms. The AUA-SI and the International Prostate Symptom Score (I-PSS) are nearly identical, validated short, self-administered questionnaires, used to assess the severity of three storage domains and related voiding symptoms. The examination includes a digital rectal examination (DRE) and a focused neurological assessment. A physical examination, including both a digital rectal examination (DRE) and a focused neurologic examination, should be performed. On DRE the examiner judges the size, shape and consistency of the gland. A firm, irregular or nodular prostate is a reason for further assessment for cancer, and the guideline treats a suspicious DRE finding as grounds for referral. If the initial evaluation reveals the presence of LUTS associated with results of a digital rectal exam suggesting prostate cancer, hematuria, abnormal prostate-specific antigen levels, recurrent urinary tract infection, palpable bladder, history/risk of urethral stricture, and/or a neurological disease raising the likelihood of a primary bladder disorder, the patient should be referred to a urologist.\n\nUrinalysis and prostate-specific antigen\n\nWhile a urinalysis cannot diagnose BPH, it can help clinicians to rule out other causes of LUTS not associated with BPH through the detection of bacteria, blood, white cells, glucose, or protein in the urine. Blood in the urine and recurrent urinary tract infection are therefore red flags that change the pathway.\n\nSerum prostate-specific antigen (PSA) is interpreted against gland size. Most men in the age group for prostate cancer usually have some BPH as well, which can elevate PSA levels and make prostate cancer diagnosis more difficult. PSA density, the PSA value divided by prostate volume, is the usual way to correct for this. A higher PSA density suggests prostatic malignancy; lower values indicate BPH. An abnormal PSA density, as defined by international consensus, is generally considered to be any value greater than 0.15 ng/mL/cc. Cut-offs vary, and higher cutoff values, such as≥0.18 ng/mL/cc, ≥0.20 ng/mL/cc, and even 0.30 ng/mL/cc, have been suggested by various studies. The PSA density is a useful parameter, but it is not definitive. Volume matters for risk as well: several studies have highlighted a significant inverse correlation between prostate volume (PV) and PCa. Clinical studies have demonstrated that patients diagnosed with PCa typically demonstrate comparatively lower PV than those diagnosed with BPH.\n\nUroflowmetry, residual urine and ultrasound\n\nUroflowmetry records the flow curve of a void. Uroflowmetry is a simple and risk-free, office-based procedure that can be an important adjunct in the evaluation of LUTS. Men with obstruction typically show decreased maximum urinary flow rate and increased voiding time. Post-void residual (PVR) volume is measured either by catheter or by bladder ultrasound scanning. To determine post-void residuals (PVR), a catheter can be inserted to completely drain the bladder, or a bladder ultrasound is used to visualize the amount of fluid that is still in the bladder. PVR can be useful in determining a baseline ability of the bladder to empty, detecting severe urinary retention that may not be amenable to medical therapy, and/or indicate detrusor dysfunction. There is no universally accepted definition of a clinically significant residual urine volume and following a trend over time is the best way to use this tool.\n\nTransrectal ultrasound estimates gland size. TRUS can be used to estimate prostatic size before surgical procedures for BPH and to identify the intravesical extension of the median lobe into the bladder. An enlarged prostate is diagnosed when the size of the gland is greater than 20 to 30 cc. The prostatic volume is typically calculated by measuring the length, height, and width, and then multiplying by the ellipsoidal formula. For surgical planning, the AUA guideline also accepts abdominal ultrasound, cystoscopy or cross-sectional imaging such as MRI or CT as ways to assess prostate size and shape. Clinicians should consider assessment of prostate size and shape via abdominal or transrectal ultrasound, or cystoscopy, or by preexisting cross-sectional imaging (i.e. magnetic resonance imaging [MRI]/ computed tomography [CT]) prior to surgical intervention for LUTS attributed to BPH.\n\nCystoscopy, urodynamics and when they are used\n\nPressure-flow urodynamics is the main test that separates bladder-outlet obstruction from detrusor weakness. Urodynamic pressure flow study tests pressure in the bladder during urination and can diagnose blockage from BPH. The guideline lists PVR, uroflowmetry, and pressure flow studies as optional studies that confirm the diagnosis or grade its severity. In practice, urodynamics is generally reserved for men whose diagnosis is uncertain, whose symptoms do not match the gland, or who have neurological disease, earlier pelvic or urethral surgery, or a failed treatment, because these groups may not be obstructed by the prostate alone. Cystoscopy is used to examine the urethra, bladder wall and median lobe, and to look for stones, tumours or stricture. In one device trial protocol, a screening cystoscopy will be performed to confirm the presence of obstructive BPH, to estimate the BPH severity, and identify any significant contribution of the median lobe to obstruction. Cystoscopy is generally indicated before surgery and in men with haematuria or a history of urethral stricture."
    },
    {
      "heading": "Conservative management and watchful waiting",
      "text": "For many men with lower urinary tract symptoms (LUTS) caused by BPH, conservative management is the first tier of care. It combines counselling, behavioural change and structured observation, and reserves drugs or procedures for men whose symptoms remain bothersome. Patients with mild symptoms (e.g., IPSS <7) should be counselled about a combination of lifestyle modification and watchful waiting. The cut-offs differ between frameworks: some describe mild bother as an IPSS below 8, not below 7 (patients with a mild degree of bother (IPSS<8) or patients with moderate to severe symptoms (IPSS≥8) who are not bothered by their LUTS may be managed with watchful waiting and lifestyle modification). A mild score with severe bother is treated differently: such men should undergo further assessment. Observation is also appropriate for men with moderate or severe scores who are not troubled by them and have no complications of BPH, since in those men medical therapy is not likely to improve their symptoms and/or quality of life.\n\nLifestyle and behavioural measures\n\nBehavioural advice is usually the first intervention. Fluid timing matters more than total volume: the usual recommendation is to drink more earlier in the day and to stop several hours before bedtime, which targets nocturia. A protocol used in a self-management trial advised a total intake of 1500-2000 mls, spread evenly through the day. Caffeine and alcohol are the main dietary targets because they increase urine production and can irritate the bladder. Some clinicians suggest omitting suspected irritants for about a week and then reintroducing them one at a time to see which ones affect symptoms. Other advice includes reducing fluid intake after 6 PM, weight loss, exercise, bladder training, and constipation management. Bladder training uses progressively longer intervals between voids to increase the volume the bladder tolerates, while timed and double voiding help reduce residual urine.\n\nMedication review\n\nConservative management includes checking the patient's existing prescriptions. Over-the-counter decongestants and antihistamines can make symptoms worse, and patients are advised to ask whether any of their medicines are contributing to their symptoms. Other drug classes that act on bladder or urethral function, such as anticholinergics and sedating antihistamines, may impair emptying and should be used with caution in men with obstructive symptoms or a large residual volume.\n\nFollow-up and escalation\n\nWatchful waiting is not passive. Men are usually reassessed at regular intervals, with watchful waiting with annual reassessment considered appropriate for mild disease. A formal symptom inventory is repeated during follow-up to track how symptoms change. A large post-void residual does not by itself rule out watchful waiting, although it may herald progression of disease. Symptom severity and residual volume also predict which men later need active treatment. In a randomised trial that compared watchful waiting with transurethral resection, 36% ultimately underwent surgery within 5 years of initiating surveillance. Another trial reported 24% crossover to surgery at 3 years among patients under watchful waiting.\n\nNatural history\n\nSymptoms tend to drift upward rather than remain fixed. In the Olmsted County cohort, there was an average increase in the International Prostate Symptom Score (IPSS) of 0.18 points per year, ranging from 0.05 for men in their fifties to 0.44 for those in their seventies. In the Medical Therapy of Prostatic Symptoms trial, symptom deterioration was the most common progression event, while AUR was rather uncommon. Outcomes vary considerably between individuals. One small follow-up study found that nearly half of the men (29 of 60) who did not have surgery no longer had symptoms of BPH, though its size limits how far that finding can be generalised. Because the Olmsted County data show relatively weak correlations were observed among the severity of LUTS, BOO and BPE, gland size alone is a poor guide to whether observation will be enough."
    },
    {
      "heading": "Pharmacological therapy",
      "text": "Drug treatment is the first-line approach for most men with moderate or bothersome lower urinary tract symptoms. The main classes act on different components of the disease: alpha-1 blockers relieve dynamic obstruction, 5-α-reductase inhibitors (5-ARIs) reduce the androgen-driven growth of the gland, and phosphodiesterase-5 (PDE5) inhibitors, antimuscarinics and beta-3 agonists target symptoms and, in some cases, erectile function or bladder storage.\n\nAlpha-1 blockers\n\nAlpha-1 blockers, including tamsulosin, alfuzosin, doxazosin, silodosin and terazosin, block the α1-adrenergic receptors in prostatic stroma, the gland capsule and the bladder neck. By reducing smooth-muscle tone, they lower urethral resistance, and symptomatic improvement usually appears within days to weeks. Because they do not reduce gland size, their benefit is confined to symptoms, and they do little to alter the long-term course. The AUA guideline lists this class as first-line medical therapy, and the European Association of Urology (EAU) recommends it as initial therapy for most patients, largely because it is generally well tolerated. Their main adverse effects follow from the same vascular and smooth-muscle actions: orthostatic hypotension, dizziness, and ejaculatory disturbance such as retrograde ejaculation. Meta-analytic data also suggest a modest increase in vascular adverse events. Before cataract surgery, clinicians need to be aware of intraoperative floppy iris syndrome, a risk specific to this class.\n\n5-α-reductase inhibitors\n\nFinasteride and dutasteride inhibit the type II and, for dutasteride, type I and II isoforms that convert testosterone into dihydrotestosterone within the prostate, lowering intraprostatic androgen levels. Their onset is slow: maximal effect on symptoms typically takes around six months. Over time they reduce prostate volume, often by about a fifth to a third, and they roughly halve serum PSA, a fact that must be accounted for when PSA is interpreted. Their distinctive value lies in long-term outcomes. In the Medical Therapy of Prostatic Symptoms (MTOPS) trial, which randomised more than 3,400 men over a mean follow-up of about 4.5 years, finasteride reduced the risk of acute urinary retention and of BPH-related surgery, an effect not seen with the alpha blocker alone. Sexual side effects, including reduced libido and erectile dysfunction, occur but are generally less frequent than with combination treatment.\n\nCombination therapy\n\nThe rationale for combining the two drug classes is that they address different components of the disease: the alpha blocker targets the dynamic component, and the 5-ARI targets the static, glandular component. The randomised trials that tested this idea have produced the strongest evidence in the field. The Combination of Avodart and Tamsulosin (CombAT) study enrolled 4,844 men and followed them for four years. Combination therapy reduced the risk of acute urinary retention or BPH-related surgery by about 66% compared with tamsulosin alone and by about 20% compared with dutasteride alone. Its symptom benefit was also greater than either monotherapy, although the magnitude differed between subgroups; the advantage was clearer in men with smaller glands (roughly 30–58 mL) than in men with larger glands. MTOPS likewise showed that combination therapy reduced clinical progression, with the greatest benefit in men with prostate volumes of about 40 mL or more.\n\nNot all trials agree. The Veterans Affairs trial and the PREDICT study did not show a benefit of adding a 5-ARI to an alpha blocker over the alpha blocker alone in their primary outcomes. A meta-analysis of randomised trials has also reported that combination therapy increases the risk of erectile dysfunction and ejaculatory problems relative to either monotherapy. For this reason, guidelines usually reserve combination therapy for men with larger glands, elevated PSA, or a high risk of progression, rather than for all patients with symptoms.\n\nPDE5 inhibitors\n\nTadalafil 5 mg once daily is the PDE5 inhibitor most studied for LUTS/BPH. Trials in which it was compared with placebo over about 12 weeks reported symptom score reductions that were modestly larger than those seen with placebo. The AUA guideline (2023 version) recommends that tadalafil be discussed as a treatment option for men with LUTS/BPH whether or not they have erectile dysfunction, and it is especially reasonable for men who also have erectile problems. The guideline advises against routinely combining tadalafil with an alpha blocker, because the combination has not shown greater symptom improvement and carries a higher risk of side effects. Conversely, the AUA allows low-dose tadalafil to be combined with finasteride on a conditional basis. The EAU places PDE5 inhibitors on a similar footing to alpha blockers, and it acknowledges that the evidence on combined use remains less consistent.\n\nAntimuscarinics and beta-3 agonists\n\nAntimuscarinic agents reduce detrusor overactivity and are considered for men whose symptoms are dominated by storage complaints such as urgency and frequency. The EAU suggests they may improve symptoms in men with moderate-to-severe LUTS and storage symptoms, either alone or alongside an alpha blocker. Their main limitation is the risk of urinary retention in men with significant voiding obstruction, so they require careful selection and monitoring. Beta-3 agonists such as mirabegron act on the detrusor without anticholinergic effects and may be offered with an alpha blocker to men with predominantly storage symptoms. Trial results are more modest: the combination of mirabegron and tamsulosin improved overactive bladder and symptom scores relative to placebo, but the differences were small in absolute terms."
    },
    {
      "heading": "Surgical and minimally invasive treatment",
      "text": "Transurethral resection of the prostate\n\nTransurethral resection of the prostate (TURP) has been the reference standard for surgical treatment of BPH for decades. Monopolar TURP was long regarded as the preferred option for glands of roughly 30 to 80 mL, and European guidance has treated it as the treatment of choice in that range. Its long-term efficacy is well documented, and it has been the comparator against which most newer techniques are judged. Large registry data illustrate its dominance: in a Medicare analysis of more than 600,000 procedures, TURP accounted for just over half of all operations, and its 5-year repeat-surgery rate was lower than that of older thermal methods such as transurethral microwave therapy. The main disadvantages are bleeding, transurethral resection (TUR) syndrome caused by absorption of irrigation fluid, incomplete resection, urethral stricture and retrograde ejaculation. Bipolar TURP, which uses saline irrigation, reduces the risk of TUR syndrome and can be performed on glands somewhat larger than the usual limit in experienced hands.\n\nEnucleation techniques\n\nEnucleation procedures remove the adenoma as a whole, which largely overcomes the size limit of conventional resection. Holmium laser enucleation of the prostate (HoLEP) dissects the adenoma from the surrounding capsule and pushes it into the bladder, where it is morcellated and removed. A 2024 meta-analysis of 13 randomised trials found similar symptom scores and flow rates to TURP over follow-up, with shorter catheterisation, shorter hospital stay, smaller haemoglobin fall and fewer transfusions after HoLEP, but longer operating times. Other trials report that HoLEP is feasible even in glands above 300 g, and that outcomes improve after the surgeon passes the learning curve. In elderly men, HoLEP has been associated with more dysuria and transient incontinence than TURP, despite shorter catheter use. Thulium fibre laser enucleation has been compared with holmium enucleation in randomised trials, with slightly less blood loss and transient incontinence after thulium. Photoselective vaporisation of the prostate (PVP) uses a laser to ablate tissue and is generally reserved for smaller glands, as vaporisation becomes less efficient in large volumes. For very large glands, open or robot-assisted simple prostatectomy remains an option, although these operations carry greater morbidity and are performed less often.\n\nMinimally invasive therapies\n\nA range of office-based or outpatient procedures has been developed to reduce bleeding, anaesthesia requirements and sexual adverse effects. Prostatic urethral lift (PUL) uses permanent implants to pull the lateral lobes apart and open the urethral channel without removing tissue. Water vapour thermal therapy (Rezūm) delivers thermal energy through steam to ablate the obstructing tissue, and can be performed under local anaesthesia. Temporary implanted nitinol devices (such as iTind) are placed to keep the urethra open and are removed after a period of remodelling. Robotic waterjet ablation (Aquablation) uses a high-pressure saline jet guided by transrectal ultrasound; a double-blind randomised trial in 181 men found it non-inferior to TURP for symptom improvement at six months. Prostatic artery embolisation (PAE) is performed by interventional radiologists, who block selected prostatic arteries so that the gland gradually shrinks. Evidence for PAE is weaker: low-quality data suggest that its short-term patient-reported and functional outcomes may be less favourable than TURP, and some payers have judged the evidence insufficient. Across these therapies, PUL and PAE are associated with better preservation of ejaculatory function, while Rezūm and Aquablation spare the verumontanum. Their efficacy and durability are generally lower than those of TURP or HoLEP, and retreatment rates are often higher.\n\nSelection of procedure\n\nChoice of operation depends mainly on prostate size, which determines whether a device or an enucleation technique is practical. Devices such as PUL are generally designed for smaller glands with limited lateral lobe enlargement, whereas enucleation and robotic waterjet techniques are used more often for large glands. The presence of a median lobe complicates matters, because it can limit the effect of implants and steam-based or vaporisation techniques, making enucleation or resection more common in that setting. Anticoagulation status is important because bleeding is a major concern for TURP and other resection techniques, and procedures with lower bleeding risk or none may be favoured for men who must continue anticoagulants. The patient's wish to preserve erection and ejaculation is also decisive: procedures that avoid the verumontanum and bladder neck are generally preferred for men who prioritise ejaculatory function, while surgeon experience and the local availability of equipment also shape the final decision."
    },
    {
      "heading": "Clinical guidelines and decision-making",
      "text": "Major guideline frameworks\n\nThe American Urological Association (AUA) and the European Association of Urology (EAU) both use a stepwise approach to lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia. The first steps are a standard initial evaluation and counselling on behavioural and lifestyle measures. Drug therapy follows, and procedures are reserved for men whose symptoms persist or who have absolute indications. The EAU advises offering an α1-blocker to men with moderate-to-severe LUTS, and it recommends PSA-guided and volume-guided selection of 5α-reductase inhibitors (5-ARIs) for men at higher risk of progression. It also advises counselling patients about the slow onset of 5-ARI action. Surgery is indicated for men with absolute indications or for those whose LUTS do not respond to drugs. The AUA's most recent full update, released in 2026, contains 62 recommendations. It places emphasis on shared decision-making and individualised care, and it acknowledges that urinary symptoms can arise from several factors besides prostate enlargement.\n\nThresholds for 5-ARI use\n\nThe two frameworks differ in how they define an enlarged gland. The AUA recommends 5-ARI monotherapy for men with LUTS who show prostatic enlargement, defined as a transrectal or other imaging volume above 30 mL, a serum PSA above 1.5 ng/mL, or palpable enlargement on digital rectal examination. The AUA notes that a minimum volume of about 30 mL is needed for a reliable 5-ARI response, and that larger glands respond more strongly. Because 5-ARIs lower serum PSA by roughly half, PSA values in treated men are interpreted after adjustment, which is why PSA monitoring is repeated during therapy. The EAU instead uses a higher volume cut-off of about 40 mL as its example of increased progression risk, and earlier EAU wording used a PSA threshold of about 1.4 ng/mL. The EAU also supplies age-specific PSA values (about 1.6 ng/mL in the fifties, 2.0 ng/mL in the sixties and 2.3 ng/mL in the seventies) that correspond to glands above 40 mL, with a stated sensitivity of 65–70% at 70% specificity. These thresholds are predictive rather than diagnostic: a PSA cut-off of 1.5 ng/mL predicts a volume above 30 mL with a positive predictive value of about 78%, so a palpable or measured enlargement remains necessary for the clinical decision.\n\nShared decision-making and patient selection\n\nBoth guidelines treat the choice of therapy as an individual judgement that weighs symptom burden, comorbidities, sexual goals and procedural risk. The EAU advises that antimuscarinic drugs be avoided when post-void residual volume exceeds 150 mL, and it advises against combination treatment in the same setting. Patients with erectile or ejaculatory concerns may favour agents with a lower sexual-side-effect profile, or procedures that spare ejaculation. Shared decisions also depend on the expected magnitude of benefit, which the EAU asks clinicians to present to patients as modest. The choice of surgical technique depends on gland size and anatomy, and the AUA specifically recommends ultrasound to assess size and median-lobe involvement before intervention, together with cystoscopy to examine the urethra and identify stricture disease.\n\nRevisions and remaining uncertainty\n\nGuidance has changed as new trials and devices have appeared. The AUA's 2023 amendment revised the statements on combination therapy and added a new recommendation on low-dose daily tadalafil with an α-blocker, reversing the 2021 advice against this combination. Low-dose tadalafil with finasteride was also introduced as a combination option. The same amendment updated statements on photoselective vaporisation, water vapour thermal therapy, laser enucleation and prostatic artery embolisation, added temporary implanted prostatic devices, and removed transurethral microwave therapy and needle ablation from active recommendations, moving them to a background section on legacy technologies. For surgery, the EAU lists bipolar or monopolar TURP as the standard for glands of 30–80 mL and offers aquablation as an alternative, while the AUA recognises transurethral incision for glands of about 30 mL or less. Evidence remains limited for the long-term durability, sexual outcomes and cost-effectiveness of several newer devices, and for the optimal volume and PSA thresholds in men of different ages and ethnic groups. Recommendations are therefore expected to continue changing as longer follow-up data accumulate."
    },
    {
      "heading": "Complications and long-term course",
      "text": "Acute urinary retention and bladder-related complications\n\nAcute urinary retention (AUR) is the most abrupt complication of BPH. A review of AUR in BPH notes that up to a third of men undergoing surgery for the condition first present with retention. Up to a third of patients undergoing surgical treatment for BPH present with acute urinary retention (AUR). Precipitants include prolonged deferral of voiding, immobilisation, urinary infection, and drugs such as anticholinergics, opioids, sympathomimetics and anaesthetics, as well as alcohol. Acute urinary retention can develop with prolonged attempts to postpone voiding, immobilization, urinary tract infections, or use of anesthetics, anticholinergics, sympathomimetics, opioids, or alcohol. Initial management is bladder decompression, usually by urethral or suprapubic catheter. The immediate treatment is bladder decompression using urethral or suprapubic catheterization. The likelihood of retention and of needing corrective surgery rises with age. The risk of AUR and the need for corrective surgery increases with age.\n\nOnce the bladder can no longer empty fully, residual urine accumulates, and this stagnant volume creates conditions for further problems. Large post-void residuals predispose to infection and bladder stones. Men with acute or chronic urinary retention usually have evidence of bladder decompensation including a large postvoid residual volume, which can also predispose to infection and bladder stones. Chronic outlet obstruction is also linked to recurrent urinary tract infection, gross haematuria and bladder calculi. Chronic bladder outlet obstruction (BOO) secondary to BPH may lead to urinary retention, impaired kidney function, recurrent urinary tract infections, gross hematuria, and bladder calculi. Clinical guidance treats recurrent stones, infection, bladder dysfunction or upper-tract dilation as reasons to refer for procedural treatment. Consider referral to a urologist for procedural intervention if symptoms persist despite medical therapy, the patient does not desire medication, or the BPH causes complications (eg, recurrent calculi or infection, bladder dysfunction, upper tract dilation).\n\nRenal consequences of chronic obstruction\n\nLong-standing obstruction can propagate backward to the kidneys. Historically, chronic end-stage obstruction often led to renal failure and uraemia. In the past, chronic end-stage BOO often led to kidney failure and uremia. Case reports of neglected disease document the mechanism: postmortem examination of one fatal case showed bilateral hydronephrosis, and histology confirmed obstructive nephropathy and renal failure. Postmortem examination revealed marked bladder distension (2500 mL), hemorrhagic cystitis, prostatic enlargement (45 g) with urethral obstruction, bilateral hydronephrosis, and renal cortical cysts. Histopathology confirmed obstructive nephropathy and renal failure. Retention can also tip a patient with existing renal impairment into acute decline, as in a case of retention with obstructive uropathy and renal failure. More serious complications of BPH include acute urinary retention and, in the case under discussion, obstructive uropathy with renal failure due to bladder outlet obstruction.\n\nSurgical risks\n\nProcedures carry their own complication profile. For transurethral resection of the prostate (TURP), a review of procedures lists significant bleeding that sometimes needs transfusion, TUR syndrome from absorbed irrigation fluid, retrograde ejaculation, erectile dysfunction and incontinence. Complications of TURP include significant bleeding (often requiring transfusions), TUR syndrome (hyponatremia secondary to absorption of hypotonic irrigation), retrograde ejaculation, impotence, and urinary incontinence. Transfusion is rare, but larger glands appear to carry higher blood-loss risk. Men with larger prostates seem to be at higher risk of heavy blood loss. Retrograde ejaculation is common after resection, though it is not harmful in itself. Many men who have a TURP lose the ability to ejaculate semen during sex or masturbation, although they still have the physical pleasure associated with ejaculation (orgasm). This is known as retrograde ejaculation. Urethral stricture and bladder-neck contracture are less frequent, and they are tracked in trial follow-up protocols. rates of complications (including urethral stricture, incontinence, bladder neck contracture, Recatheterisation, UTI, and retrograde ejaculation).\n\nRetrospective data suggest that retention at the time of surgery matters. In one analysis of monopolar TURP, patients who presented with AUR had larger glands and worse outcomes, which the authors linked to higher complication risk. The findings of this study highlight the increased risks of complications associated with AUR in patients undergoing monopolar TURP. Group A, comprising patients with AUR, exhibited a significantly larger mean prostate volume (45.8 g) compared to 42.3 g in Group B, with a p-value of 0.03.\n\nPredictors of progression\n\nCohort studies have sought variables that identify men at risk of retention, surgery or medical failure. Baseline prostate volume and serum PSA are repeatedly described as the most consistent predictors of progression. the most important and consistent predictive factors for BPH progression are baseline prostate-specific antigen and prostate volume. Age, flow rate and residual volume have also been associated with progression. Age, flow rate, and postvoid residual also were significant predictors of progression. Progression in trials has been defined broadly, including worsening symptoms, retention, renal insufficiency, recurrent infection and incontinence. BPH progression was defined as IPSS worsening of ≥4 points from baseline, acute urinary retention, renal insufficiency, recurrent urinary tract infection or urinary incontinence The benefit of finasteride appears to concentrate in men with higher symptom scores and PSA levels. The greatest absolute benefit of finasteride on symptoms and the reduction in risk of AUR and surgery was in men with higher baseline symptom scores and a baseline PSA level of 1.4 ng/mL or greater.\n\nPredictive performance is modest. In an observational cohort of men failing medical therapy, the best cut-offs for symptom score and volume gave areas under the ROC curve of about 0.67 and 0.65. According to the ROC curve-based prediction of the failure for medical therapy, the best cutoff values of IPSS and prostate volume were 21 (area under ROC curve: 0.67) and 32 cm^3 (area under ROC curve: 0.65), respectively. Most progression data also derive from larger glands, so predictors may differ in small-volume disease. Most data on BPH progression derive from cohorts with moderate‐to‐large prostates (>30 ml), in which static obstruction from glandular enlargement predominates."
    },
    {
      "heading": "Relationship to prostate cancer and other conditions",
      "text": "Coexistence with prostate cancer\n\nBPH and prostate cancer often occur in the same man, and their anatomical origins differ. BPH nodules arise mainly in the transition zone, whereas most prostate cancers arise in the peripheral zone. Epidemiological data nonetheless show an association between them. A 2019 systematic review and meta-analysis reported that the association between BPH and prostate cancer was strongest after studies with major outliers were excluded, with a pooled odds ratio of about 3.1 across eight studies. The estimate was lower, about 2.2, across 21 studies with very high heterogeneity. A preprint genetic analysis found that the diagnoses correlate partly through shared inherited polygenic risk, which suggests the link is not explained by detection bias alone.\n\nPSA, rectal examination and imaging\n\nSerum PSA is produced by both benign and malignant prostatic epithelium, so a larger gland produces more PSA even without cancer. Many men with BPH have elevated PSA, and in such men occult cancer, prostatic intraepithelial neoplasia or acute inflammation may account for the rise. Serial increases therefore warrant closer evaluation, and a single high value is not diagnostic. Clinicians use PSA velocity, PSA density (PSA divided by gland volume) and age-specific reference values to improve specificity. Because PSA density depends on an accurate volume, transrectal ultrasonography or magnetic resonance imaging is used to measure the gland, and multiparametric MRI can help target biopsy when cancer is suspected. The digital rectal examination complements these tests: BPH typically produces smooth, symmetrical enlargement, whereas firm, asymmetrical or nodular induration of the peripheral zone raises suspicion of cancer. Newer biomarker panels are being studied for this purpose. In one exploratory serological study of 49 men with cancer, 70 with BPH and 28 controls, distinguishing cancer from BPH reached only about 70% accuracy, rising to about 84% when a PSA threshold was added.\n\nDifferential diagnosis\n\nProstatitis is a major alternative explanation for urinary symptoms and PSA elevation. A meta-analysis reported that prostatitis was associated with prostate cancer, and case-control and cohort studies suggested that prostatitis may increase the subsequent risk of BPH. Other conditions that mimic BPH-related symptoms must be excluded, including urinary tract infection, neurogenic bladder from spinal cord or peripheral nerve disease (including diabetic neuropathy), urethral stricture after instrumentation, trauma or inflammation, bladder neck contracture, detrusor underactivity, bladder stones and bladder cancer. Uroflowmetry, post-void residual measurement, urinalysis and, where indicated, cystoscopy or ultrasound help separate these causes from outflow obstruction due to the prostate.\n\nCardiovascular and metabolic overlap\n\nAlpha-1 blockers lower blood pressure by relaxing vascular smooth muscle, so orthostatic hypotension is a recognised adverse effect, particularly in volume-depleted patients. Its incidence in randomised trials was close to placebo levels with alfuzosin and tamsulosin, but higher with terazosin and doxazosin. The non-selective agents are therefore less suitable for men taking several antihypertensive drugs. Tamsulosin added to atenolol, enalapril or nifedipine produced no clinically significant additional blood-pressure effect in interaction studies. Combining doxazosin or terazosin with phosphodiesterase-5 inhibitors increases the risk of orthostasis, whereas silodosin, which has the highest alpha-1A selectivity, carries the lowest orthostatic risk but the highest rate of ejaculatory disturbance. Interaction studies with pharmacological partners also matter: co-administration of mirabegron with tamsulosin raised tamsulosin exposure by about 60% without a clinically relevant change in blood pressure or heart rate. Epidemiological links between BPH and obesity, diabetes, metabolic syndrome and cardiovascular disease have been described, but these are largely observational and their causal direction remains unclear, so they should not by themselves determine treatment choice.\n\nSexual function\n\nTreatment choice is strongly shaped by sexual goals. The 5-alpha-reductase inhibitors finasteride and dutasteride are associated with decreased libido, erectile dysfunction and ejaculatory disorders; a meta-analysis of randomised trials reported increased odds of ejaculatory disorder and decreased libido compared with placebo. Reports of persistent sexual dysfunction and a possible association with depression have prompted continuing debate. Alpha-1 blockers more commonly cause ejaculatory disturbance, and the effect is most pronounced with tamsulosin and silodosin. Men with erectile or ejaculatory concerns may therefore be steered toward alternatives such as agents with lower ejaculatory effects, or toward phosphodiesterase-5 inhibitors where erectile dysfunction coexists with LUTS. Procedural options also differ in their effect on ejaculation, which is discussed in the surgical section."
    },
    {
      "heading": "History of discovery and therapeutic development",
      "text": "Early descriptions and open surgery\n\nAnatomical study of the gland came before operative treatment. The Venetian anatomist Nicolo Massa is usually credited with the first real description of the prostate, in the sixteenth century. The earliest recorded operation on the gland was a transperineal incision made with the patient in the lithotomy position, attributed to the French urologist Joseph Covillard in 1639 . Urethral approaches followed. George James Guthrie's 1830 blind incision of the bladder neck was often complicated by bleeding and incontinence, because the surgeon had no clear view of the operative field . In 1895 Eugene Fuller published six cases of suprapubic prostatectomy . Terence Millin's retropubic route, described in 1945, was designed to reduce the complication rate of these earlier open operations . Open prostatectomy remains the oldest surgical treatment for moderate-to-severe lower urinary tract symptoms and is generally reserved for very large glands, conventionally above about 80 mL .\n\nEndoscopic resection\n\nThe shift to endoscopic surgery depended on instrumentation. In 1897 A. Freudenberg paired earlier urethral methods with the cystoscope, ending what is called the blind era . Edwin Beer introduced high-frequency electrical current to the operation in 1910 . Transurethral resection of the prostate (TURP) was reported in 1931 and became the standard operation for decades . In the 1980s it was already a frequently performed procedure, and reported rates later fell sharply as drug therapy and minimally invasive options spread, from roughly 230–270 per 100,000 people in 1980–1991 to about 131 per 100,000 in 1994 . In a Turkish multicentre series, the share of monopolar TURP fell from 77.9% to 17.9% between 2016 and 2019 .\n\nPharmacological development\n\nMedical therapy began in the mid-1970s with nonselective alpha-blockers such as phenoxybenzamine, and receptor-selective agents later became the first-line choice . The 5-α-reductase inhibitors followed a longer path. After animal studies showed that finasteride lowered dihydrotestosterone and prostate volume, it entered human trials in 1986 . The US Food and Drug Administration approved it on 19 June 1992 for symptomatic BPH, and the phase III results appeared in the New England Journal of Medicine the same year . Its action, competitive inhibition of type II 5α-reductase with suppression of serum DHT by about 70%, is described in . Dutasteride came later, and sources differ on its approval year, giving 2001 in one review  and October 2002 in another . The Medical Therapy of Prostatic Symptoms (MTOPS) trial randomised over 3,400 men to doxazosin, finasteride or both, and over a mean follow-up of 4.5 years the longer-term reductions in acute retention and surgery were seen with the 5-ARI arms .\n\nLaser and office-based procedures\n\nLaser surgery entered the field in the 1990s. Gilling and colleagues described the first holmium resection technique for the prostate in 1996 . Holmium laser enucleation of the prostate (HoLEP) and photoselective vaporisation of the prostate (PVP) are now the best-studied laser options and dominate laser practice . PVP has been performed with a 120 W GreenLight system in comparative studies . HoLEP is reported to produce size-independent cavities comparable to open surgery, with lower perioperative morbidity . Adoption differs across health systems. In a seven-centre Israeli series covering 2010–2022, TURP accounted for 72% of 13,478 procedures, open surgery for 12%, HoLEP for 12% and PVP for 3% . In emerging economies, open transvesical prostatectomy continues to be a common treatment ."
    },
    {
      "heading": "Open questions and current research",
      "text": "Although the broad outline of BPH is well described, the causal chain that starts and sustains enlargement remains only partly mapped. Hormones, inflammation, metabolic state and ageing each have supporting evidence, yet there is no agreed hierarchy among them. Inflammation illustrates the problem. Prostatic enlargement may be caused directly by inflammatory activities that stimulate prostate growth or indirectly by inflammatory processes that reduce prostatic apoptosis. Both routes are plausible, and the relative weight of each in a given man is unknown. It is also unresolved whether inflammation initiates the process, sustains it, or mainly marks tissue injury. Metabolic links are similarly ambiguous. A study of genetic variants linked to metabolic disorders reported a genome-wide significant association with prostate volume, and the men with larger glands shared risk factors such as age, body mass index, waist-to-hip ratio and statin use. These overlaps point to shared biology without establishing which condition drives the other.\n\nBiomarkers are a central research aim because clinicians lack a reliable way to forecast which men will progress. Unlike prostate cancer, there are currently no recognized phenotypes that predict BPH severity or progression. In practice, decisions still rest on gland size and serum PSA until symptoms become severe enough to require intervention. Candidate markers are emerging. In a study of tissue from 96 men undergoing transurethral resection, CYR61 and VEGF expression might serve as biomarkers for predicting the clinical progression of BPH due to effects on stromal cell proliferation and angiogenesis. Urine is also being examined, since oxidative-stress and inflammatory profiles appear to differ among men whose lower urinary tract symptoms have different causes. Imaging is another route. In a retrospective cohort of 154 men who underwent MRI and urodynamic testing, an MRI-derived spherical volume ratio independently predicted progression, although the follow-up averaged only about a year.\n\nGenetic research has grown but remains incomplete. Estimates from electronic-record cohorts suggest a heritability near 60%, somewhat higher than the 49% derived from earlier twin studies. A large genome-wide association study of 20,621 patients and 280,541 controls of European ancestry identified 23 genome-wide significant variants, located at 14 loci. Many of these variants also track with serum PSA, which complicates their use as clinical markers. A review noted that four genome-wide association studies and two Mendelian randomization studies have been carried out, but no meta-analyses are yet available. Polygenic scores may eventually help stratify risk. In a Han Chinese study, mean prostate volume increased significantly across the PRS quartiles, from 34.6 ± 19.0 mL in Q1 to 43.1 ± 25.0 mL in Q4.\n\nThe mismatch between gland size and symptoms is among the least explained features of the disease. Histological change starts early, yet symptoms usually appear only after several decades, and not every man with histological BPH develops LUTS. Large glands may be silent, and small glands may cause marked obstruction. The fibrous capsule is one candidate explanation, because it concentrates obstructive force at the bladder neck, but the link between size and symptoms is modest. In one cohort, prostate volume showed only a weak correlation with symptom scores. Drug responses vary in a similar way: an analysis of six studies found that finasteride improved symptoms only in men whose initial prostate volume exceeded 40 cubic centimetres. Bladder compensation, smooth-muscle tone and individual sensitivity to obstruction are therefore likely to matter, but their relative importance has not been quantified.\n\nLong-term evidence for newer minimally invasive devices is also limited. Many of these technologies were introduced on the basis of short-term trials, and their durability, retreatment rates, effects on sexual and ejaculatory function, and cost-effectiveness relative to established operations are still being followed up. Comparisons are complicated by differences in follow-up length, patient selection and reimbursement settings, so results across health systems are not directly interchangeable. Ongoing prospective studies aim to clarify where these procedures fit into the treatment pathway, but firm conclusions about their lasting value are not yet available."
    }
  ],
  "links": [
    "hormone",
    "epidemiology",
    "medicine",
    "public-health",
    "cancer",
    "cell",
    "cell-division",
    "magnetic-resonance-imaging",
    "ultrasonography",
    "biopsy",
    "enzyme",
    "gene-expression",
    "apoptosis",
    "chronic-kidney-disease",
    "kidney",
    "infectious-disease",
    "biomarker",
    "surgery",
    "randomized-controlled-trial",
    "informed-consent",
    "hypertension",
    "pharmacology",
    "obesity",
    "diabetes-mellitus",
    "metabolism",
    "cardiovascular-disease",
    "inflammation"
  ],
  "sources": [
    {
      "title": "MRI of Benign Prostatic Hyperplasia: Important Pre- and Posttherapeutic Considerations",
      "url": "https://pubs.rsna.org/doi/full/10.1148/rg.220096"
    },
    {
      "title": "MRI Evaluation of Patients Before and After Interventions for Benign Prostatic Hyperplasia: An Update",
      "url": "https://www.ajronline.org/doi/10.2214/AJR.21.26278"
    },
    {
      "title": "Benign Prostatic Hyperplasia (BPH): Practice Essentials, Background, Anatomy",
      "url": "https://emedicine.medscape.com/article/437359-overview"
    },
    {
      "title": "Systems and methods for treating the prostate",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11786287"
    },
    {
      "title": "Benign Prostatic Hyperplasia - StatPearls - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK558920/"
    },
    {
      "title": "The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Healthy Longevity",
      "url": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(22)00213-6/fulltext"
    },
    {
      "title": "Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3989819/"
    },
    {
      "title": "Prevalence, Burden, and Treatment of Lower Urinary Tract Symptoms in Men Aged 50 and Older: A Systematic Review of the Literature - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7774430"
    },
    {
      "title": "BPH: Epidemiology and Comorbidities",
      "url": "https://www.ajmc.com/view/apr06-2288ps122-s128"
    },
    {
      "title": "Full article: Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50–69 years with PSA ≥3 ng/ml",
      "url": "https://www.tandfonline.com/doi/full/10.1080/21681805.2019.1703806"
    },
    {
      "title": "Benign Prostatic Hyperplasia",
      "url": "https://nutritionguide.pcrm.org/nutritionguide/view/Nutrition_Guide_for_Clinicians/1342049/all/Benign_Prostatic_Hyperplasia"
    },
    {
      "title": "Associations between metabolic syndrome and clinical benign prostatic hyperplasia in a northern urban Han Chinese population: A prospective cohort study",
      "url": "https://www.nature.com/articles/srep33933"
    },
    {
      "title": "Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23234610/"
    },
    {
      "title": "Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence of a Potential Relationship, Hypothesized Etiology, and Prevention - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3162215/"
    },
    {
      "title": "Metabolic Syndrome and Benign Prostatic Hyperplasia/Which Component of Metabolic Syndrome Is Related to Benign Prostatic Hyperplasia? - Journal of Urological Surgery",
      "url": "https://jurolsurgery.org/articles/metabolic-syndrome-and-benign-prostatic-hyperplasiawhich-component-of-metabolic-syndrome-is-related-to-benign-prostatic-hyperplasia/jus.galenos.2023.2022.0081"
    },
    {
      "title": "Epidemiology of benign prostatic hyperplasia: risk factors and concomitance with hypertension - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7519437/"
    },
    {
      "title": "Predictors of the international prostate symptoms scores for patients with lower urinary tract symptoms: A descriptive cross-sectional study - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6060591/"
    },
    {
      "title": "Risk factors for benign prostatic hyperplasia: a comprehensive review - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12245072/"
    },
    {
      "title": "Association between benign prostatic hyperplasia, body mass index, and metabolic syndrome in Chinese men - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4577599/"
    },
    {
      "title": "Composition for preventing, improving or treating benign prostatic hyperplasia or alopecia, comprising heat-killed probiotics as active ingredient",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12667595"
    },
    {
      "title": "Stromal SRD5A2 promotes prostate growth through WNT5A-LEF1-IGF1 signaling in benign prostatic hyperplasia",
      "url": "https://www.biorxiv.org/content/10.1101/2025.05.22.655540.full.pdf"
    },
    {
      "title": "Stromal resistance to castration-induced prostate regression in a mouse model of benign prostatic hyperplasia",
      "url": "https://www.biorxiv.org/content/10.1101/2022.12.07.519520.full.pdf"
    },
    {
      "title": "(PDF) The Role of Hormonal Changes in the Development of Benign Prostatic Hyperplasia: A Mini Review",
      "url": "https://www.researchgate.net/publication/389838072_The_Role_of_Hormonal_Changes_in_the_Development_of_Benign_Prostatic_Hyperplasia_A_Mini_Review"
    },
    {
      "title": "Endocrine control of benign prostatic hyperplasia - La Vignera - 2016 - Andrology - Wiley Online Library",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/andr.12186"
    },
    {
      "title": "Understanding the role of estrogen in the development of benign prostatic hyperplasia - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S1110570418300055"
    },
    {
      "title": "Estrogen regulation in the prostate underlies racial disparity in men with benign prostatic hyperplasia",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12805628/"
    },
    {
      "title": "Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943333/"
    },
    {
      "title": "The etiology and pathogenesis of benign prostatic hyperplasia：The ro",
      "url": "https://www.dovepress.com/the-etiology-and-pathogenesis-of-benign-prostatic-hyperplasia-the-role-peer-reviewed-fulltext-article-RRU"
    },
    {
      "title": "UP-3.087: Castration as a Treatment in Benign Prostatic Hyperplasia: A Historical Review - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0090429509020603"
    },
    {
      "title": "Androgens and estrogens in benign prostatic hyperplasia: past, present and future - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3179830/"
    },
    {
      "title": "Pathogenesis and medical treatment of benign prostatic hyperplasia - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/2482776/"
    },
    {
      "title": "Castration‐like effects on the human prostate of a 5α‐reductase inhibitor, finasteride",
      "url": "https://onlinelibrary.wiley.com/doi/10.1002/jcb.240501225"
    },
    {
      "title": "SRD5A2 in the development of benign prostatic hyperplasia mechanism and immune infiltration analysis",
      "url": "https://www.researchsquare.com/article/rs-3878653/v1"
    },
    {
      "title": "The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S221438821930102X"
    },
    {
      "title": "Stromal Proliferation in Benign Prostatic Hyperplasia",
      "url": "https://encyclopedia.pub/entry/47536"
    },
    {
      "title": "Senescent mast cells contribute to the progression of benign prostatic hyperplasia via SCF/c-KIT mediated endothelial-mesenchymal transition",
      "url": "https://www.biorxiv.org/content/10.1101/2025.06.02.657200.full.pdf"
    },
    {
      "title": "Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia",
      "url": "https://doi.org/10.3390/ijms17081311"
    },
    {
      "title": "MOLECULAR AND CELLULAR PATHOGENESIS OF BENIGN PROSTATIC HYPERPLASIA",
      "url": "https://www.auajournals.org/doi/10.1097/01.ju.0000133655.71782.14"
    },
    {
      "title": "Growth factors in benign prostatic hyperplasia: Basic science implications",
      "url": "https://link.springer.com/article/10.1007/s11934-008-0048-6"
    },
    {
      "title": "Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17182170/?dopt=Abstract"
    },
    {
      "title": "Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease? - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S030228380601582X"
    },
    {
      "title": "The Link Between Benign Prostatic Hyperplasia and Inflammation - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1569905613000377"
    },
    {
      "title": "Chronic inflammation in the pathogenesis of benign prostatic hyperplasia - Fibbi - 2010 - International Journal of Andrology - Wiley Online Library",
      "url": "https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2605.2009.00972.x"
    },
    {
      "title": "The role of macrophage migration inhibitory factor in promoting benign prostatic hyperplasia epithelial cell growth by modulating COX-2 and P53 signaling",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673366/"
    },
    {
      "title": "Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease",
      "url": "https://www.researchgate.net/publication/6618484_Is_Benign_Prostatic_Hyperplasia_BPH_an_Immune_Inflammatory_Disease"
    },
    {
      "title": "The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917596/"
    },
    {
      "title": "A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003138/"
    },
    {
      "title": "Bicyclic substituted hexahydrobenz ›e! isoindole alpha-1 adrenergic antagonists",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5792767"
    },
    {
      "title": "Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7091200"
    },
    {
      "title": "The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0026895X25101569"
    },
    {
      "title": "Alpha 1 adrenoceptor subtypes in the human prostate - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8094762/"
    },
    {
      "title": "α1-ADRENOCEPTOR SUBTYPE SELECTIVITY",
      "url": "https://www.mayoclinicproceedings.org/article/S0025-6196(11)62191-5/pdf"
    },
    {
      "title": "Characterization of alpha-1 adrenoceptor subtypes in human and canine prostate membranes - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7996431"
    },
    {
      "title": "Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7244738"
    },
    {
      "title": "Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6358959"
    },
    {
      "title": "Characterization of Alpha1 Adrenergic Receptors in Human Benign Prostatic Hyperplasia",
      "url": "https://www.auajournals.org/doi/10.1016/S0022-5347%2817%2950110-X"
    },
    {
      "title": "Role of alpha‐adrenergic blockers in the treatment of benign prostatic hyperplasia - Lepor - 1990 - The Prostate - Wiley Online Library",
      "url": "https://onlinelibrary.wiley.com/doi/10.1002/pros.2990170508"
    },
    {
      "title": "Pharmacology of α1-adrenoceptor antagonists in the lower urinary tract and central nervous system",
      "url": "https://www.nature.com/articles/ncpuro0836"
    },
    {
      "title": "Alpha1 Adrenoceptor Subtypes in the Human Prostate - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0022534717361700"
    },
    {
      "title": "Identification, Quantification, and Localization of mRNA for Three Distinct Alpha1 Adrenergic Receptor Subtypes in Human Prostate - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0022534717355441"
    },
    {
      "title": "Effects of androgen deprivation on prostate alpha1-adrenergic receptors - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0090429596001835"
    },
    {
      "title": "Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8548177"
    },
    {
      "title": "Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans",
      "url": "https://bmcurol.biomedcentral.com/articles/10.1186/s12894-018-0329-4"
    },
    {
      "title": "Benign Prostatic Hyperplasia - Urology - MSD Manual Professional Edition",
      "url": "https://www.msdmanuals.com/professional/genitourinary-disorders/benign-prostate-disease/benign-prostatic-hyperplasia"
    },
    {
      "title": "Bladder Outlet Obstruction - an overview",
      "url": "https://www.sciencedirect.com/topics/veterinary-science-and-veterinary-medicine/bladder-outlet-obstruction"
    },
    {
      "title": "Biology and Time Course of Obstruction-Induced Detrusor Underactivity Causing Postvoid Residual Urine",
      "url": "https://www.einj.org/journal/view.php?doi=10.5213%2Finj.2652010.005"
    },
    {
      "title": "Lower Urinary Tract Symptoms and Benign Prostate Hyperplasia",
      "url": "https://www.urotoday.com/volume-5-2012/vol-5-issue-6/53854-lower-urinary-tract-symptoms-and-benign-prostate-hyperplasia.html"
    },
    {
      "title": "Can BPH Damage the Kidneys? Retention & Hydronephrosis",
      "url": "https://prostate-treatment-options.com/bph-kidney-damage.html"
    },
    {
      "title": "Histomorphology of trabeculated urinary bladder",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0003277814000227"
    },
    {
      "title": "Diagnosis and Management of Benign Prostatic Hyperplasia",
      "url": "https://www.aafp.org/pubs/afp/issues/2008/0515/p1403.html"
    },
    {
      "title": "Benign prostatic hyperplasia and urinary symptoms: Evaluation and treatment - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25823641/"
    },
    {
      "title": "Benign Prostatic Hyperplasia - Urology - Merck Manual Professional Edition",
      "url": "https://www.merckmanuals.com/professional/genitourinary-disorders/benign-prostate-disease/benign-prostatic-hyperplasia"
    },
    {
      "title": "Benign prostatic hyperplasia and male lower urinary symptoms: A guide for family physicians - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S2214388217300516"
    },
    {
      "title": "International Prostate Symptom Score",
      "url": "https://en.wikipedia.org/wiki/International_Prostate_Symptom_Score"
    },
    {
      "title": "Compositions and methods for improving sexual function",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10335453"
    },
    {
      "title": "Prospective Sexual Function Study for BPH Subjects",
      "url": "https://clinicaltrials.gov/study/NCT01777269"
    },
    {
      "title": "Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter",
      "url": "https://cdn.clinicaltrials.gov/large-docs/79/NCT03423979/Prot_001.pdf"
    },
    {
      "title": "International Prostate Symptom Score Guide",
      "url": "https://www.medbridge.com/blog/international-prostate-symptom-score"
    },
    {
      "title": "[Evaluation of sexual function in men with symptomatic benign prostatic hyperplasia] - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/16078666/"
    },
    {
      "title": "Minimally Invasive Prostatic Vapor Ablation for the Treatment of BPH in Large Prostates (Rezūm XL)",
      "url": "https://cdn.clinicaltrials.gov/large-docs/45/NCT03605745/Prot_SAP_000.pdf"
    },
    {
      "title": "Enlarged Prostate",
      "url": "https://medlineplus.gov/enlargedprostatebph.html"
    },
    {
      "title": "Acute urinary retention in men: 21‐year trends in incidence, subsequent benign prostatic hyperplasia‐related treatment and mortality: A Danish population‐based cohort study - Bengtsen - 2023 - The Prostate - Wiley Online Library",
      "url": "https://onlinelibrary.wiley.com/doi/10.1002/pros.24440"
    },
    {
      "title": "Acute Urinary Retention and Severe Hyponatremia in a Patient With a Large Intramural Uterine Fibroid",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450083/"
    },
    {
      "title": "Prostatic Urethral Lift in Subject With Acute Urinary Retention",
      "url": "https://cdn.clinicaltrials.gov/large-docs/37/NCT03194737/Prot_SAP_000.pdf"
    },
    {
      "title": "Acute urinary retention in benign prostatic hyperplasia: Risk factors and current management",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721562/"
    },
    {
      "title": "Acute urinary retention in men: 21‐year trends in incidence, subsequent benign prostatic hyperplasia‐related treatment and mortality: A Danish population‐based cohort study - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10087475/"
    },
    {
      "title": "Risk Factors for Acute Urinary Retention in Patients With Benign Prostatic Hyperplasia From the Islamic Republic of Iran",
      "url": "https://www.urotoday.com/volume-3-2010/vol-3-issue-6/40193-risk-factors-for-acute-urinary-retention-in-patients-with-benign-prostatic-hyperplasia-from-the-islamic-republic-of-iran-2233113.html"
    },
    {
      "title": "Correlation of Subjective Symptoms in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5364794/"
    },
    {
      "title": "Correlation between intravesical prostatic protrusion and ejaculatory dysfunction after tamsulosin treatment in men with BPH",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12913309/"
    },
    {
      "title": "management of lower urinary tract symptoms attributed to ...",
      "url": "https://www.auanet.org/documents/Guidelines/PDF/2023%20Guidelines/BPH%20Unabridged%2002-20-24%20Final.pdf"
    },
    {
      "title": "AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendations",
      "url": "https://www.auajournals.org/doi/full/10.1097/01.ju.0000078083.38675.79"
    },
    {
      "title": "Management of Benign Prostatic Hyperplasia (BPH)",
      "url": "https://www.auanet.org/documents/Guidelines/PDF/Benign-Prostatic-Hyperplasia-2010.pdf"
    },
    {
      "title": "Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia",
      "url": "https://www.exchangecme.com/resourcePDF/bph/resource2.pdf"
    },
    {
      "title": "Transrectal Ultrasound for Prostate Cancer",
      "url": "https://hillman.upmc.com/cancer-care/prostate/screenings/transrectal-ultrasound"
    },
    {
      "title": "Transrectal Ultrasonography and Image-Guided Biopsies of the Prostate - StatPearls - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK570569/"
    },
    {
      "title": "Correlation of Transrectal Ultrasonography Guided Prostate Biopsy Gleason Score Results with Prostate Volume in Patients with Prostate Specific Antigen Level Between 2.5-10 ng/mL - Journal of Urological Surgery",
      "url": "https://jurolsurgery.org/articles/correlation-of-transrectal-ultrasonography-guided-prostate-biopsy-gleason-score-results-with-prostate-volume-in-patients-with-prostate-specific-antigen-level-between-25-10-ngml/doi/jus.galenos.2024.2024-2-4"
    },
    {
      "title": "https://doi.org/10.1177/1557988320938969 American Journal of Men’s Health",
      "url": "https://journals.sagepub.com/doi/pdf/10.1177/1557988320938969"
    },
    {
      "title": "Uroflow Post-Void Residuals",
      "url": "https://www.adventhealth.com/practice/adventhealth-medical-group/uroflow-post-void-residuals"
    },
    {
      "title": "bph-2018.pdf",
      "url": "https://www.auanet.org/documents/guidelines/archive/bph-2018.pdf"
    },
    {
      "title": "Benign Prostatic Hyperplasia (BPH): Symptoms, Diagnosis & Treatment - Urology Care Foundation",
      "url": "https://www.urologyhealth.org/urology-a-z/b/benign-prostatic-hyperplasia-(bph)"
    },
    {
      "title": "Optilume™ BPH Catheter System in Men With Symptomatic BPH",
      "url": "https://cdn.clinicaltrials.gov/large-docs/07/NCT04131907/Prot_000.pdf"
    },
    {
      "title": "BPH Surgical Management 091219.pub",
      "url": "https://www.auanet.org/documents/Guidelines/Archive/BPH-2019.pdf"
    },
    {
      "title": "Benign Prostatic Hyperplasia (BPH) Workup: Approach Considerations, Urinalysis and Urine Culture, Prostate-Specific Antigen",
      "url": "https://emedicine.medscape.com/article/437359-workup"
    },
    {
      "title": "UPDATE",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9343161/"
    },
    {
      "title": "Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction and other diseases or symptoms",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11291703"
    },
    {
      "title": "Benign Prostatic Hyperplasia (BPH) Treatment & Management: Approach Considerations, Alpha-Blockers, 5-Alpha-Reductase Inhibitors",
      "url": "https://emedicine.medscape.com/article/437359-treatment"
    },
    {
      "title": "Self-management for Men With Uncomplicated Lower Urinary Tract Symptoms",
      "url": "https://clinicaltrials.gov/study/NCT00270309"
    },
    {
      "title": "Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH) - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S2950393025000993"
    },
    {
      "title": "AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendations",
      "url": "https://www.auajournals.org/doi/10.1097/01.ju.0000078083.38675.79"
    },
    {
      "title": "The natural history of benign prostatic hyperplasia - FITZPATRICK - 2006 - BJU International - Wiley Online Library",
      "url": "https://bjui-journals.onlinelibrary.wiley.com/doi/abs/10.1111/j.1464-410X.2006.06097.x"
    },
    {
      "title": "The natural history of benign prostatic hyperplasia: what have we learned in the last decade? - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0090429500007470"
    },
    {
      "title": "Insights into the Natural History and Treatment of Benign Prostatic Hyperplasia",
      "url": "https://auajournals.org/doi/10.1016/S0022-5347(05)00765-2"
    },
    {
      "title": "Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction and other diseases or symptoms",
      "url": "https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11045511"
    },
    {
      "title": "Lifestyle and Management options for Prostate Diseases",
      "url": "https://www.healthinaging.org/a-z-topic/prostate-diseases/lifestyle"
    },
    {
      "title": "Bladder control: Lifestyle strategies ease problems - Mayo Clinic",
      "url": "https://www.mayoclinic.org/diseases-conditions/urinary-incontinence/in-depth/bladder-control-problem/art-20046597"
    },
    {
      "title": "BPH Management Through Lifestyle Changes - Aquablation® US",
      "url": "https://aquablation.com/blog/bph-management-through-lifestyle-changes/"
    },
    {
      "title": "Therapy combination superior in high-risk BPH patients",
      "url": "https://www.urologytimes.com/view/therapy-combination-superior-high-risk-bph-patients"
    },
    {
      "title": "The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S2214388217300929"
    },
    {
      "title": "Full article: Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis",
      "url": "https://www.tandfonline.com/doi/full/10.1080/13685538.2016.1195361"
    },
    {
      "title": "Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169865/"
    },
    {
      "title": "Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S221438821730053X"
    },
    {
      "title": "Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I—Initial Work-up and Medical Management",
      "url": "https://www.auajournals.org/doi/10.1097/JU.0000000000002183"
    },
    {
      "title": "Benign Prostatic Hyperplasia: EAU 2024 Guideline Expert Insight",
      "url": "https://reference.medscape.com/cc1/p10/top-tips-benign-prostatic-hyperplasia-2024a1000a5f"
    },
    {
      "title": "Pharmacologic Treatment of Benign Prostatic Hyperplasia",
      "url": "https://www.premera.com/medicalpolicies/5.01.545.pdf"
    },
    {
      "title": "A Review of Combined Phosphodiesterase-5-Inhibitors and α-Blockers versus Phosphodiesterase-5-Inhibitors Alone for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10776071/"
    },
    {
      "title": "Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29061225/"
    },
    {
      "title": "Large review: TURP still gold standard for BPH",
      "url": "https://www.urologytimes.com/view/large-review-turp-still-gold-standard-bph"
    },
    {
      "title": "BPH treatment: laser for everyone | Opinion: NO",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050566/"
    },
    {
      "title": "An update on transurethral surgery for benign prostatic obstruction - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S2214388217300577"
    },
    {
      "title": "Holmium laser enucleation of the prostate versus transurethral resection of the prostate in treatment of benign prostatic hyperplasia: A meta-analysis of 13 randomized control trials - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12042171/"
    },
    {
      "title": "Holmium Laser Enucleation of the Prostate (HoLEP) Versus Transurethral Resection of the Prostate (TURP) in Elderly Patients: Insights Into Recovery, Complications, and Risk Factors",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11761158/"
    },
    {
      "title": "Holmium Versus Thulium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis of Randomized Controlled Trials - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S2405456921001036"
    },
    {
      "title": "Holmium laser enucleation of the prostate: Learning curve analysis and comparison with TURP - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12924071/"
    },
    {
      "title": "Research progress on ejaculatory function preservation in minimally invasive surgical treatments for benign prostatic hyperplasia: a narrative review - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12541510/"
    },
    {
      "title": "Frontiers",
      "url": "https://www.frontiersin.org/journals/urology/articles/10.3389/fruro.2025.1641171/full"
    },
    {
      "title": "Benign Prostatic Hyperplasia (BPH) Treatments",
      "url": "https://wa-provider.kaiserpermanente.org/static/pdf/hosting/clinical/criteria/pdf/bph_treatments.pdf"
    },
    {
      "title": "An Update on Minimally Invasive Surgery for Benign Prostatic Hyperplasia: Techniques, Risks, and Efficacy - :: WJMH :: World Journal of Men's Health",
      "url": "https://wjmh.org/DOIx.php?id=10.5534%2Fwjmh.190076"
    },
    {
      "title": "The role of Rezum in the management of refractory urinary retention due to benign prostate hyperplasia: A literature review",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373601/"
    },
    {
      "title": "BPH Surgery and Minimally Invasive Procedures: TURP, HoLEP, UroLift, Rezūm, Aquablation and PAE",
      "url": "https://factbasedurology.com/prostate/prostate-psa/procedures/"
    },
    {
      "title": "Reoperation after surgical treatment for benign prostatic hyperplasia: a systematic review - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10665564/"
    },
    {
      "title": "Benign Prostatic Hyperplasia: Rapid Evidence Review",
      "url": "https://www.aafp.org/afp/2023/0600/benign-prostatic-hyperplasia"
    },
    {
      "title": "Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12497387/"
    },
    {
      "title": "BPH Treatment Guidelines 2025: Expert-Validated Algorithm For Patient Care GlobalRPH",
      "url": "https://globalrph.com/2025/12/bph-treatment-guidelines-2025-expert-validated-algorithm-for-patient-care/"
    },
    {
      "title": "Managing Benign Prostatic Hyperplasia - Continuing Education",
      "url": "https://journalce.powerpak.com/ce/managing-benign-prostatic-hyperplasia"
    },
    {
      "title": "Disease Management - EAU Guidelines on the Management of Non-neurogenic Male LUTS - Uroweb",
      "url": "https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/disease-management"
    },
    {
      "title": "EAU Non-Neurogenic Male Lower Urinary Tract Symptoms Guideline Summary - Guideline Central",
      "url": "https://www.guidelinecentral.com/guideline/4543231/"
    },
    {
      "title": "Diagnostic Evaluation - EAU Guidelines on the Management of Non-neurogenic Male LUTS - Uroweb",
      "url": "https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/diagnostic-evaluation"
    },
    {
      "title": "Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms - European Urology",
      "url": "https://www.europeanurology.com/article/S0302-2838(23)02731-8/fulltext"
    },
    {
      "title": "EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23541338/"
    },
    {
      "title": "AUA Guideline Articles Management of Lower Urinary Tract Symptoms",
      "url": "https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000003698"
    },
    {
      "title": "AUA releases guideline amendments for BPH-related LUTS and testicular cancer",
      "url": "https://www.urologytimes.com/view/aua-releases-guideline-amendments-for-bph-related-luts-and-testicular-cancer"
    },
    {
      "title": "AUA BPH guideline amendment explained",
      "url": "https://www.auadailynews.org/aua-2024/article/22908990/aua-bph-guideline-amendment-explained"
    },
    {
      "title": "Benign Prostatic Hyperplasia (BPH) Guidelines: Guidelines Summary",
      "url": "https://emedicine.medscape.com/article/437359-guidelines"
    },
    {
      "title": "American Urological Association Releases the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline - American Urological Association",
      "url": "https://www.auanet.org/about-us/media-center/press-center/aua-releases-the-management-of-luts-attributed-to-bph-guideline"
    },
    {
      "title": "Updated AUA guidelines on BPH: What urologists need to know",
      "url": "https://www.urologytimes.com/view/updated-aua-guidelines-bph-what-urologists-need-know"
    },
    {
      "title": "Renal Failure Due to Benign Prostatic Hyperplasia",
      "url": "https://psnet.ahrq.gov/web-mm/renal-failure-due-benign-prostatic-hyperplasia"
    },
    {
      "title": "Fatal obstructive uropathy secondary to neglected benign prostatic hyperplasia: A medico-legal case report - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12826211"
    },
    {
      "title": "Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)",
      "url": "https://cdn.clinicaltrials.gov/large-docs/89/NCT02930889/Prot_SAP_001.pdf"
    },
    {
      "title": "Transurethral resection of the prostate (TURP)",
      "url": "https://johnsonmemorial.org/jmh-health-information-tests/prc-20206614"
    },
    {
      "title": "Transurethral resection of the prostate (TURP)",
      "url": "https://www.nhsinform.scot/tests-and-treatments/surgical-procedures/transurethral-resection-of-the-prostate-turp/"
    },
    {
      "title": "Outcomes and Efficacy of Ejaculatory Preserving Transurethral Resection of Prostate",
      "url": "https://cdn.clinicaltrials.gov/large-docs/19/NCT05914519/Prot_SAP_000.pdf"
    },
    {
      "title": "Retrospective Assessment of Post-Transurethral Resection of the Prostate Complications in Benign Prostatic Hyperplasia Patients: Impact of Acute Urinary Retention",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584171/"
    },
    {
      "title": "The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia",
      "url": "https://link.springer.com/article/10.1007/s11934-004-0049-z"
    },
    {
      "title": "Association between predictors of progression of benign prostatic hyperplasia and moderate-to-severe prostatitis-like symptoms: A propensity score–matched analysis - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9036114/"
    },
    {
      "title": "Identification of Baseline Clinical Factors Which Predict Medical Treatment Failure of Benign Prostatic Hyperplasia: An Observational Cohort Study - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0302283803001994"
    },
    {
      "title": "Bedside risk score for medical therapy failure in small‐volume BPH: Temporal validation - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13125953/"
    },
    {
      "title": "Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)",
      "url": "https://cdn.clinicaltrials.gov/large-docs/19/NCT02505919/Prot_002.pdf"
    },
    {
      "title": "Shared Inherited Genetics of Benign Prostatic Hyperplasia and Prostate Cancer",
      "url": "https://www.medrxiv.org/content/10.1101/2021.12.10.21267604.full.pdf"
    },
    {
      "title": "Correlation between Prostatitis, Benign Prostatic Hyperplasia and Prostate Cancer: A systematic review and Meta-analysis",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930406/"
    },
    {
      "title": "PSA in benign prostatic hyperplasia and prostatic intraepithelial neoplasia - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7505969"
    },
    {
      "title": "Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454546/"
    },
    {
      "title": "Prostate Health: PSA Numbers, BPH, and Cancer Risk Explained",
      "url": "https://www.gaurology.com/your-psa-level-is-high-now-what/"
    },
    {
      "title": "Orthostatic Hypotension in Benign Prostatic Hyperplasia Patients and Its Association With Alpha-1 Antagonist Use: A Comprehensive Literature Review",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518119/"
    },
    {
      "title": "Alpha 1 -Adrenergic Blockers: Current Usage Considerations",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1111/j.1524-6175.2005.05300.x"
    },
    {
      "title": "A Comparison of Varying α-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1477612/"
    },
    {
      "title": "Review of Medical Therapy Options in Updated AUA Guidelines for BPH Management, Journal Club - Rashid Sayyid & Zachary Klaassen",
      "url": "https://www.urotoday.com/video-lectures/journal-clubs/video/3764-review-of-medical-therapy-options-in-updated-aua-guidelines-for-bph-management-journal-club-rashid-sayyid-zachary-klaassen.html"
    },
    {
      "title": "A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)",
      "url": "https://cdn.clinicaltrials.gov/large-docs/73/NCT02656173/Prot_001.pdf"
    },
    {
      "title": "Side Effects of 5‐Alpha Reductase Inhibitors: A Comprehensive Review - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S2050052115300615"
    },
    {
      "title": "Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S2050052118300891"
    },
    {
      "title": "291 The History for Surgical Treatment of Benign Prostatic Hyperplasia",
      "url": "https://academic.oup.com/jsm/article-abstract/14/Supplement_1/S86/7011027"
    },
    {
      "title": "Trends in benign prostatic hyperplasia surgery over the years: A multicenter 14-year retrospective study - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9612752/"
    },
    {
      "title": "Recent advances in the surgical treatment of benign prostatic hyperplasia - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3229249/"
    },
    {
      "title": "5α-Reductase: History and Clinical Importance - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1472916/"
    },
    {
      "title": "5-alpha reductase inhibitors use in prostatic disease and beyond - Chislett - Translational Andrology and Urology",
      "url": "https://tau.amegroups.org/article/view/111026/html"
    },
    {
      "title": "5-alpha Reductase Inhibitors vs Alpha Blockers",
      "url": "https://www.withpower.com/guides/5-alpha-reductase-inhibitors-vs-alpha-blockers-8b7d"
    },
    {
      "title": "Laser Prostatectomy: Holmium Laser Enucleation and Photoselective Laser Vaporization of the Prostate - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3651537/"
    },
    {
      "title": "Comparison of Photoselective Vaporization versus Holmium Laser Enucleation for Treatment of Benign Prostate Hyperplasia in a Small Prostate Volume",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881985/"
    },
    {
      "title": "Greenlight Vaporization vs Xpeeda Vaporesection",
      "url": "https://clinicaltrials.gov/study/NCT04386941"
    },
    {
      "title": "Transformations in Benign Prostatic Hyperplasia Surgical Practices: A Longitudinal Study of Trends and Predictions - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12140584/"
    },
    {
      "title": "Surgical management of benign prostate hyperplasia in Nigeria: open prostatectomy versus transurethral resection of the prostate",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434791/"
    },
    {
      "title": "Diagnostic efficacy of systemic immune-inflammation biomarkers in benign prostatic hyperplasia using receiver operating characteristic and artificial neural network - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10491602/"
    },
    {
      "title": "Targeting phenotypic heterogeneity in benign prostatic hyperplasia - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5669834/"
    },
    {
      "title": "Correlation between molecular biomarkers and risk factors for the clinical progression of benign prostatic hyperplasia using tissue microarray immunostaining - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/25430444"
    },
    {
      "title": "Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12249731/"
    },
    {
      "title": "The predictive value of prostate spherical volume ratio in lower urinary tract symptoms and clinical progression of benign prostatic hyperplasia: a retrospective cohort study",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12167308/"
    },
    {
      "title": "Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network",
      "url": "https://www.nature.com/articles/s41598-019-42427-z"
    },
    {
      "title": "Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA",
      "url": "https://www.nature.com/articles/s41467-018-06920-9"
    },
    {
      "title": "Genetic Predisposition to Benign Prostatic Hyperplasia: Where Do We Stand? - ScienceDirect",
      "url": "https://www.sciencedirect.com/science/article/pii/S266616832401098X"
    },
    {
      "title": "Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese",
      "url": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-024-00619-3"
    },
    {
      "title": "The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia - PubMed",
      "url": "https://pubmed.ncbi.nlm.nih.gov/15260926/"
    },
    {
      "title": "(PDF) Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network",
      "url": "https://www.researchgate.net/publication/332419235_Heritability_and_genome-wide_association_study_of_benign_prostatic_hyperplasia_BPH_in_the_eMERGE_network"
    },
    {
      "title": "Benign Prostatic Hyperplasia (BPH)",
      "url": "https://www.hopkinsmedicine.org/health/conditions-and-diseases/benign-prostatic-hyperplasia-bph"
    },
    {
      "title": "Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume",
      "url": "https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0132028"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}